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ABSTRACT 
 
The aim of this study is to determine the cytotoxic and apoptotic effects of 
erythrocarpine E (CEB4), a new limonoid extracted from Chisocheton erythrocarpus. 
MTT assay, Live/Dead® Viability/Cytotoxicity assay, cell cycle analysis, annexin V 
analysis, PARP cleavage analysis, DNA fragmentation assay, sandwich ELISA assay 
and Western blot analysis were performed on  five CEB4 treated cancer cell lines; 
HSC4COX2- and HSC2 (oral), CaSki (cervical), HepG2 (liver), MCF7 (breast) and 
NHBE (normal human bronchial epithelial cell line). CEB4 treated HSC4COX2-, HSC2, 
CaSki, HepG2 and MCF7 cells demonstrated a cytotoxic effect and inhibited cell 
proliferation in a dose and time dependent manner. CEB4 had minimal effect on NHBE. 
Cell cycle analysis of treated cancer cells detected a hypodiploid sub-G1 peak in all the 
cancer cell lines expect in the HSC2 cells confirming CEB4 induced apoptosis. The 
shift in percentage in the G0/G1 phase in HSC4COX2-, CaSki, and HepG2 cells suggested 
a possible G0/G1 arrest of the cancer cells upon treatment with CEB4 at 12 hours. 
Annexin V analysis by flow cytometry, PARP cleavage analysis, and DNA 
fragmentation results showed that CEB4 induces apoptosis in CEB treated cancer cell 
lines. The results of the ELISA analysis suggest that CEB4 induced apoptosis may be 
mediated by p53, a tumour suppressor gene. Western blot results demonstrated that 
CEB4 induce growth arrest and apoptosis in HSC4COX2- cells appeared to be mediated 
through regulation of p53 signalling pathway as there is an increase in expression of 
phosphorylated p53 and decrease in expression of the p53 inhibitor, Mdm2. CEB4 up-
regulates pro-apoptotic gene, Bax and at the same time down-regulate the anti-apoptotic 
gene, Bcl-2. It also activates activator caspase 9 and executioner caspase 3, which are 
downstream molecules to induce apoptosis. These results demonstrated the cytotoxic 
and apoptotic ability of this compound and suggest its potential use as a cancer 
chemopreventive agent.  
 xvii 
ABSTRAK 
 
Kajian ini telah di jalankan untuk menyiasat sama ada erythrocarpine E (CEB4), ekstrak 
baru daripada Chisocheton erythrocarpus, mempunyai kesitotoksikan dan mekanisma 
kematian sel (apoptosis) ke atas lima jenis sel-sel kanser, mulut (HSC4COX2- dan HSC2), 
servik (CaSki), hati (HepG2), payu dara (MCF7) dan sel normal dari epitelia bronkus 
manusia (NHBE ). Kesan ketoksikan dan mekanisma kematian sel ditentukan melalui 
cherakin MTT, asei Live/Death, analisa kitaran sel, analisa annexin V, analisa PARP, 
asei DNA fragmentasi, assei sandwich ELISA dan asei Western blot. CEB4 mempunyai 
kesan sitotoksik keatas HSC4COX2-, HSC2, CaSki, HepG2 dan MCF7 serta menghalang 
proliferasi sel bergantung pada dose dan masa. CEB4 memberi kesan minima pada 
epitelia bronkus manusia normal, NHBE. Analisis kitaran sel sel kanser kecuali sel 
HSC2 menunjukkan puncak sub-G1 di mana mengesahkan apoptosis oleh CEB4 keatas 
sel sel kanser ini. Pengurangan sel sel kanser di fasa G0/G1 pada HSC4COX2-, CaSki, dan 
HepG2 selepas rawatan dengan CEB4 selama 12 jam mencadangkan kemungkinan CEB4 menghalang 
proliferasi sel di fasa G0/G1. Analisa annexin V, analisa PARP dan asei DNA fragmentasi  
menunjukkan CEB4 menginduksi apoptosis keatas semua sel. Analisa ELISA p53 
menunjukkan CEB4 mungkin menyebabkan kematian sel-sel kanser yang dimediasi 
oleh p53 suatu gene  tumour suppressor’. Analisa Western menunjukkan kematian 
keatas sel kanser mulut, HSC4 COX2- telah dimediasi melalui regulasi laluan isyarat p53 
kerana terdapat penambahan dalam ekspresi posforilasi p53 dan penurunan dalam 
ekspresi penghalang p53, Mdm2. CEB4 meningkatkan regulasi gen pro-apoptotik Bax, 
dan pada masa yang sama menurunkan regulasi gen anti-apototik, Bcl-2. Ia juga 
mengaktifkan kaspas pengaktifan 9 dan kaspas eksekusi 3, iaitu molekul protein yang 
terlibat di akhir mekanisma kematian sel. Keputusan ini membuktikan yang sitotoksik 
dan kemampuan apoptotik sebatian ini menyarankan potensinya digunakan sebagai 
agen rawatan kanser.  
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CHAPTER 1.0: INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 Cancer 
 
 According to the National Cancer Institute (NCI), cancer is a term used for a 
group of diseases in which cells in a part of the body start to grow out of control form a 
mass of tissue. Transformed cells are able to invade other tissues. Cancer cells often 
travel to other parts of the body, where they begin to grow and form new tumors that 
replace normal tissue. This process is called metastasis. There are more than 100 
different types of cancer and the name of most cancers comes from the name of the 
organ or type of cell that the cancer started to arise from or also known as the primary 
site.  
The main categories of cancer include:  
• Carcinoma - cancer that begins in the skin or in tissues that line or cover                                                               
   internal organs.  
• Sarcoma -  cancer that begins in bone, cartilage, fat, muscle, blood vessels,   
           or other connective or supportive tissue.  
• Leukemia -  cancer that starts in blood-forming tissue such as the bone    
           marrow and causes large numbers of abnormal blood cells to  
   produced and enter the blood.  
• Lymphoma and myeloma - cancers that begin in the cells of the immune  
               system.  
• Central nervous system cancers - cancers that begin in the tissues of the                               
       brain and spinal cord.  
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 There are several views which explain the mechanisms of how cancers arise and 
two interrelated yet contrasting views will be discussed here. One view gives the 
proposition for the formation of cancers due to the rare simultaneous acquisition of 
two interdependent conditions on the same cell at the same time. These conditions are 
deregulated cell proliferation and suppressed apoptosis. Having either one condition 
will not be sufficient to form cancer because deregulated proliferation alone induces 
cell death. On the other hand, suppressed apoptosis without deregulated proliferation 
would not expand uncontrollably. Therefore, the combination of these two conditions 
forms a sort of a basic foundation for all neoplasms to arise (Evan and Littlewood, 
1998).  
 The second view states that most types of human cancer have been suggested to 
have acquired capabilities or traits through a multistep process. The process alters the 
genome of cancer cells at multiple sites with changes such as point mutations to even 
changes in chromosome complement and each alteration would confer one or another 
type of growth advantage which is similar to Darwinian evolution (Hanahan and 
Weinberg, 2000). 
 Essentially, there are six acquired capabilities from tumorigenesis that give a 
cancer cell its genotype and they are: 1) self-sufficiency in growth signals, 2) 
insensitivity to growth-inhibitory (antigrowth) signals, 3) escape from programmed 
cell death (apoptosis), 4) limitless replicative potential, 5) sustained angiogenesis, and 
6) tissue invasion and metastasis (Hanahan and Weinberg, 2000).Acquisition of each 
of these six capabilities during tumorigenesis represents the breakdown of an intrinsic 
anticancer defence mechanism in cells and tissues. The particular sequence where 
these capabilities are acquired varies widely whether among same or different tumour  
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types. The mutations that occur in oncogenes or tumour suppressor genes are also 
variable where it can either be early in some tumorigenesis pathways or late in others 
(Hanahan and Weinberg, 2000). 
 However, both views state the importance of acquiring certain conditions or 
capabilities before a normal somatic cell has the selective advantage to transform into 
a cancerous cell and overcome the multiple anticancer defences (Hanahan and 
Weinberg, 2000).This implies that the probability of getting cancer is very low and yet 
we see cases of it happening very often. The reason for such a ‘paradox’ might be due 
to the “wear away” of mechanisms that limit somatic cell proliferation through 
prolonged and random accumulation of multiple mutations (Evan and Littlewood, 
1998).  
1.2 Cancer statistics  
 
 
 Cancer can affect everybody and is considered the highest killer after 
cardiovascular diseases (Chuah et al., 2006). Kamangar et al., 2006 reported a 
worldwide estimation of 11 million cancer incidences, 7 million cancer deaths and 
about 25 million individuals were living with cancer. Cancer of lung, stomach, colon 
and rectum, liver, and oesophagus are seen as being of the highest incidence, while 
cancer of prostate, female breast, uterine and cervix are common sex-specific cancer. 
  
 A total of 21,464 cancer cases comprising 9,400 males and 12,064 females were 
diagnosed among Malaysians in Peninsular Malaysia according to the Second Report of 
the National Cancer Registry (NCR) in 2003.Cancer can occur at all ages. The median 
age at diagnosis for cancer in Malaysia for males and females was 59 year old and 53  
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year old, respectively in 2003. Leukemia, brain cancer, lymphoma, connective tissue 
cancer and kidney cancer are the five top incidences of cancers in children of 0-14 years 
old (Lim and Halimah, 2004). 
 
 In the group of young adults of 15-49 years old, the common cancers were 
nasopharynx, leukemia, lymphoma, lung, colon and rectum in men, and cancers of the 
breast, cervix, ovary, uterus, thyroid gland and leukemia in women. In the group of 
people 50 years old and above, cancers of the lung, colon, rectum, nasopharynx, 
prostate and stomach were common among men, while cancers of the breast, cervix, 
colon, uterus, lung and rectum occurred frequently in women (Lim and Halimah, 2004). 
 
1.2.1 Oral cancer  
 
 
 According to the World Health Organization (WHO), 267,000 cases of oral 
cancers were newly diagnosed worldwide, around 40% (108,843 cases) occurred in 
India, Pakistan, Bangladesh, and Sri Lanka. South Asia has almost twice incidence and 
mortality rates of oral cancer than global rates (Ahluwalia, 2005). In Peninsular 
Malaysia, the NCR reported that for the year 2002, oral cancer was ranked 21st and 16th 
most common cancer among males and females respectively. However, oral cancer 
incidence has increased to 19th for males, and 16th for females in 2003 (Lim and 
Halimah, 2004).  
 
 A nationwide prevalence study on oral mucosal lesions were carried out in 
1993/4 and reported that there was a variation seen in the occurrence of oral pre-
malignancy among the ethnic groups. The Indians, followed by the indigenous people 
of Sabah and Sarawak were identified as groups with higher risk for oral cancer and 
pre-cancer. It has been observed that both of these ethnic groups chewed betel quid. 
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1.2.2 Cervical cancer  
 
 Squamous cell carcinoma and adenocarcinoma are the two main types of 
cervical cancer where 80 to 90% of them are of the squamous cell type while the 
adenocarcinoma type makes up the remaining 10 to 20%. There is also a less common 
type of cervical cancer where it has features of both mixed squamous cell carcinomas 
and adenocarcinomas (Syrjanen, 1989). 
 
 The single most important cause of cervical cancer would be due to infection 
from a virus called Human Papillomavirus (HPV), and about 95% of cervical cancers 
have been found to be HPV positive (Syrjanen, 1989). Studies found that the two 
oncogenes that are capable of inducing epithelial cell immortalization in culture alone, 
and increase cellular transformation with other oncogenes are the E6 and E7. Both 
genes are found in high-risk HPV strains such as HPV16 and HPV18 (Pecoraro et al., 
1989). The E6 and E7 oncogenes work to promote cell transformation by binding to two 
important tumour suppressor genes p53 and pRB respectively and disrupting their 
normal cellular function (Scheffner et al., 1990). 
 
 The estimated number of new cases and deaths due to cervical cancer in the US 
according to the NCI registry in 2008 was 11,070 and 3,870 respectively while in the 
UK there are 2,800 new cases each year. In Malaysia, cervical cancer is the second most 
frequent cancer being diagnosed in females at 12.9% ((Lim and Halimah, 2004). 
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1.2.3 Breast cancer  
  
 
 Breast cancer is the second most common cancer and the most common cancer 
among women worldwide, with an estimated 1,152,161 new cases and 411,093 deaths 
per year (Kamangar et al., 2006). Hormones, exposures, family history, alcohol 
consumption, early menarche, late menopause, low parity and postmenopausal obesity 
are established risk factors for breast cancer (Kolonel et al., 2004). 
 
 Lim and Halimah, 2004 reported that breast cancer was the most commonly 
diagnosed type of cancer among females in Peninsular Malaysia, with prevalence of 
3,738 female breast cancer cases with 31.0% new cases in the year 2003. Breast cancer 
was the most common cancer in all ethnic groups and all age groups in females starting 
from the age of 15 years.  
 
1.2.4 Liver cancer  
 
 
 Primary liver cancers are uncommon among people in the Western countries but 
are more common in Africans and Asians, and it should not be confused with secondary 
liver cancer which is a metastasis of a cancer from another part of the body. Most 
primary liver cancer starts in liver cells called hepatocytes and this type of cancer is 
called hepatocellular carcinoma or malignant carcinoma while children may develop 
childhood hepatocellular carcinoma.  
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 The secondary sites that liver cancer usually spread to would be the lymph 
nodes, lungs and bones. In the US, the estimated number of new cases and deaths from 
liver and intrahepatic bile duct cancer are 21,370 and 18,410 respectively in the NCI 
registry, 2008 while in the UK, 3,120 people were diagnosed with liver cancer in 2005 
accounting for only 1% of all cancers diagnosed. In Malaysia, liver cancer accounts for 
4% of all cancers in males and in females 1.3% of all cancers (Lim and Halimah, 2004).  
 
1.3 Cancer cell lines 
 
 
1.3.1 Oral HSC4COX2- and HSC2 cancer cell lines 
 
 The cell lines used to represent oral cancers in this study are HSC4COX2- and 
HSC2. There was no additional information on the two cell lines in the literature due to 
lack of characterization work. However, the difference between the two cell lines is that 
HSC2 has constitutively high COX-2 gene activity while HSC4COX2- only expressed 
normal levels (Akita et al., 2006). Cyclooxygenase-2 (COX-2) is an inducible enzyme 
that regulates prostaglandin synthesis and is overexpressed at sites of inflammation and 
in several epithelial cancers (figure1.1). COX-2 is involved in the regulation of 
apoptosis, angiogenesis, and tumour cell invasiveness, which appear to contribute to its 
effects on tumorigenesis. 
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Figure 1.1: Biochemical pathways catalyzed by COX-2. (Adapted from Cyclooxygenase-2: a 
novel target for cancer chemotherapy. Dempke et al., 2001) 
 
 
 
1.3.2 Cervical CaSki cancer cell line 
 
 
 CaSki cancer cell lines have epithelial-like morphology. It was extracted from a 
40 year old Caucasian female with an epidermoid carcinoma of the cervix metastatic to 
the small bowel mesentery. Almost all of the cervical cancers are caused by the 
infection of double-stranded DNA viruses, human papillomaviruses (HPV) on epithelial 
cells of the skin and the anogenital or oropharyngeal mucosa. The most common type of 
human papillomaviruses (HPVs) are HPV types 16, 18, 31, and 33 which encode two 
oncoproteins, E6 - early protein 6 and E7 - early protein 7 (Yee et al., 1985). 
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 Both oncoproteins play major roles in contributing to the carcinogenic process 
and are capable of altering proliferation and apoptosis, as well as inducing 
immortalization of primary human keratinocytes. These proteins are capable of 
interacting and facilitating the proteolytic degradation of cellular proteins that regulates 
the cell cycle clock and apoptosis such as p53 and pRb, respectively, which are potential 
mechanisms by which these viral proteins induce tumours (Wu et al., 2006). 
 
 
1.3.3 Breast MCF7 cancer cell line 
 
 The cancer cell line used to represent breast cancer in this study was MCF7 
which was derived from a pleural effusion discovered after the removal of nodules in 
the chest wall of a 69 year-old Caucasian woman in 1970 (Dickson et al., 1986). 
 
 Some of the characteristics of the cell line would be the expression of E-
cadherin (Hiraguri et al., 1998), epidermal growth factor receptor (Biscardi et al., 1998), 
estrogen receptor (Hall et al., 1990), and progesterone receptor (Sutherland et al., 1988). 
In addition, the cell line is tested negative for expression of basic fibroblast growth 
factor (Li and Shipley, 1998) and vimentin (Sommers et al., 1989). 
 
 
1.3.4 Liver HepG2 cancer cell line 
 
 HepG2 is a human liver carcinoma cell line that was derived from the liver 
biopsy of a 15 year old Caucasian male with a well differentiated hepatocellular 
carcinoma (Aden et al., 1979). HepG2 is an aneuploid cell line with a modal number of 
55 chromosomes which range from 50-60 chromosomes. HBV surface antigens have 
not been detected in HepG2 (Kim and Kim, 2004).  
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 Maruyama et al., 2007 reported that the expression levels of albumin and α-
fetoprotein (AFP) mRNAs remain unchanged, while the levels of expression of 
cytochrome P450 (CYP) genes such as CYP3A4, CYP3A5, and CYP3A7 mRNAs 
decreased gradually in HepG2. The mRNA expression of major CYP isoforms 
including CYP3As such as CYP1A2, CYP2A6, CYP2B6, CYP2C (2C9 and 2C19), 
CYP2D6, and CYP2E1 can be detected in HepG2 cells.  
   
1.4 Cancer and apoptosis  
 
 
 Two major mechanisms of cell death are apoptosis and necrosis. In apoptosis, or 
programmed cell death, the cells undergo death to control cell proliferation in response 
to DNA damage (Ghobrial et al., 2005). 
 
 The term apoptosis is based on the morphological characteristics of the dying 
cells, which include cellular shrinkage, membrane blebbing and eventually 
fragmentation into membrane bound apoptotic bodies (Figure 1.2). During apoptosis, 
the cell membrane loses its asymmetry, and phosphatidylserine (PS) becomes exposed 
on the cell surface. This PS exposure act as signal for macrophages, which can mediate  
the effective clearance of apoptotic cell. This type of cell death does not trigger 
inflammation (de Bruin et al., 2008).  
  
 In contrast, necrosis is generally known as a “non-specific” form of cell death, 
characterised by breaking of the plasma membrane which results in an unfavourable 
localized inflammatory response and damage to neighbouring cells and tissues 
(Kroemer et al., 1998). 
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Figure1.2: Hallmarks of the apoptotic and necrotic cell death process. Apoptosis includes 
cellular shrinking, chromatin condensation and margination at the nuclear periphery with the 
eventual formation of membrane-bound apoptotic bodies that contain organelles, cytosol and 
nuclear fragments and are phagocytised without triggering inflammatory processes. The 
necrotic cell swells, becomes leaky and finally is disrupted and releases its contents into the 
surrounding tissue resulting in inflammation. (Adapted from Apo Review: Introduction to 
Apoptosis. Gewies, 2003) 
 
 
 
1.4.1 Apoptosis signaling  
 
  
            Apoptosis is a highly regulated cell death program which requires the interaction of 
complex machinery controlled by complex pathways including extrinsic, intrinsic, p53, 
ubiquitin/proteosome and nuclear factor kappa B pathways and also by Bcl-2 family 
members. Among the several pathways identified, extrinsic or cytoplasmic and intrinsic 
or mitochondrial pathways are among two major pathways that are involved in 
apoptosis (Ghobrial et al., 2005). 
 
 
 
 
 
 12 
 
 
 
1.4.2 The extrinsic and intrinsic pathway 
 
  
 The extrinsic pathway involves engagement of particular ‘death’ receptors that 
belong to the tumour necrosis factor receptor (TNF-R) family and, through the 
formation of the death-inducing-signalling-complex (DISC) (Ashkenazi and Dixit., 
1998), leads to a cascade of activation of caspases, which in turn induces apoptosis 
(figure 1.2). The intrinsic pathway is triggered in response to DNA damage and is 
associated with mitochondrial depolarization and release of cytochrome c from the 
mitochondrial intermembrane space into the cytoplasm. Cytochrome c, apoptotic 
protease-activating factor 1 (Apaf- 1) and procaspase 9 then form a complex termed the 
apoptosome, in which caspase 9 is activated and promotes activation of caspases 3, 6 
and 7. Activation of these caspases triggers activation of downstream apoptotic proteins 
and induce apoptosis (Nicholson and Thornberry, 2003). 
 
 
Figure 1.3: Receptor-mediated caspase activation at the DISC. Upon ligation by its cognate 
ligand, the trimeric death receptor recruits adaptor molecules via its cytoplasmic death domains 
(DD). Besides possessing DDs, the adaptors additionally contain death effector domains (DED) 
which recruit procaspase 8 to the receptor complex which now is called the death-inducing 
signalling complex (DISC).The initiator caspase 8 cleaves and thereby activates effector 
caspases for the execution of apoptosis. (Adapted from Apo Review: Introduction to Apoptosis. 
Gewies, 2003). 
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Death receptors of the extrinsic pathway belong to the tumour necrosis factor 
receptor (TNFR) gene superfamily, including TNFR-1, Fas/CD95, and the TRAIL 
receptors DR-4 and DR-5. The TNFR family consist of cysteine rich extracellular sub-
domains which recognize specific ligands, resulting in the trimerization and activation 
of particular death receptor which contains a conserved sequence known as the death 
domain (DD).  
 
Adaptor molecules such as FADD or TRADD are recruited to the DDs of the 
activated death receptor which forms the death inducing signalling complex (DISC) 
(Figure 1.3). The adaptor FADD also contains death effector domains (DED) which 
through homotypic DED-DED interaction seize procaspase 8 to the DISC. Active 
caspase-8 then processes downstream effector caspases which subsequently cleave 
specific substrates resulting in cell death (Gewies, 2003).  
 
p53 can activate the extrinsic apoptotic pathway through the induction of genes 
encoding by transmembrane proteins such as Fas and DR5.  Fas is activated by binding 
of its ligand, FasL, which is expressed predominantly by T cells (Muzio, 1998). p53 
induces Fas mRNA expression by binding to elements found in the promoter and first 
intron of the Fas gene (Muller et al., 1998). This induction occurs in response to γ-
irradiation, and is strictly tissue specific, demonstrated in the spleen, thymus, kidney 
and lung, but not in heart and liver (Bouvard et al., 2000).  
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In addition to stimulating Fas transcription, overexpressed p53 may enhance 
levels of Fas at the cell surface by promoting trafficking of the Fas receptor from the 
Golgi (Bennett et al., 1998). This may allow p53 to rapidly sensitize cells to Fas 
induced apoptosis. 
 
The second member of the TNF-R receptor family that is induced by p53 is 
DR5/KILLER, the death-domain-containing receptor for TNF-related apoptosis-
inducing ligand (TRAIL). DR5 is induced by p53 in response to DNA damage and in 
turn promotes cell death through caspase 8 (Wu et al., 1997). DR5 induction is cell type 
specific. Whole body γ-irradiation induces DR5 expression in the spleen, small intestine 
and thymus (Burns et al., 2001), which is reliable with DR5 participating in the p53-
mediated response to DNA damage in these tissues.  
 
 In some cases the signal from the activated receptor does not generate strong 
signal for execution of cell death on its own. In this case, the signal needs to be 
amplified via mitochondria-dependent apoptotic pathways also known as the intrinsic 
apoptotic pathway (Figure 1.4). The intrinsic apoptotic pathway is dominated by the 
Bcl-2 family of proteins, which direct the release of cytochrome c from the 
mitochondria. 
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Figure 1.4: Mitochondria-mediated caspase activation at the apoptosome. A. Apoptotic stimuli 
trigger the release of apoptogenic factors from the mitochondrial intermembrane space to the 
cytosol, such as cytochrome c which induces the formation of the apoptosome and the activation 
of procaspase-9. B. By the action of cytochrome c (Cyto C) and dATP the Apaf-1 protein 
adopts a conformation that allows the formation of the apoptosome. Procaspase-9molecules can 
bind to the inner “hub” region of the apoptosome and are activated by dimer formation. Active 
caspase-9 dimers further mediate activation of effector caspases. (Adapted from Apo Review: 
Introduction to Apoptosis. Gewies, 2003) 
 
 
The link between the caspase signalling cascade and the mitochondria is 
provided by the Bcl-2 family member Bid. Bid is cleaved by caspase 8 and in its 
condensed form (tBID) translocates to the mitochondria where work together with the 
pro-apoptotic Bcl-2 family members Bax and Bak to induce the release of cytochrome c 
and other mitochondrial pro-apoptotic factors into the cytosol.  
 
Cytosolic cytochrome c binds to monomeric Apaf-1 which then, in a dATP-
dependent conformational change, oligomerizes to assemble the apoptosome, a complex 
of wheel-like structure with 7 fold symmetry that triggers the activation of the initiator 
procaspases 9.  
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The dimerization of procaspases 9 molecules at the Apaf-1 scaffold is responsible for 
caspase 9 activation. Activated caspase 9 subsequently initiates a caspase cascade 
involving downstream effector caspases such as caspase 3, 7, and 6, resulting in cell 
death. p53 promotes cytochrome c release through the induction of target genes 
encoding BH3-only proteins.  Importantly, p53 also induces Apaf-1 expression through 
a response element within the Apaf-1 promoter (Figure 1.5). 
 
 
 
Figure 1.5: Schematic representation of some major apoptotic signalling pathways. Apoptosis 
can be induced in response to various signals from inside and outside the cell, e.g. by ligation of 
so called death receptors or by cellular stress triggered by oncogenes, irradiation or drugs. 
Organelles such as mitochondria, nucleus, ER and lysosomes are important in apoptotic 
signalling pathways, and hundreds of proteins are part of an extremely fine-tuned regulatory 
network consisting of pro- and anti-apoptotic factors. (Adapted from Apo Review: Introduction 
to Apoptosis. Gewies, 2003). 
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1.5 Bcl-2 family members 
 
Bcl-2 protein family are categorized into two major groups; anti-apoptotic and 
pro-apoptotic based on their functional properties. Anti-apoptotic protein members such 
as Bcl-2 and Bcl-XL act as repressor of apoptosis, which suppresses the release of 
cytochrome c from the mitochondrion whereas pro-apoptotic proteins such as Bax and 
Bad act as promoter to induce apoptosis. Besides that, the Bcl-2 family proteins also can 
be divided according to their BH3 domain organization.  
 
 
The BH3 domain, which is present in all members and is essential for 
heterodimerization among members, is the minimum domain required for the pro-
apoptotic function. Anti-apoptotic proteins such as Bcl-XL, Bcl-2, Bcl-XL, Bcl-w, 
possess the domains BH1, BH2, BH3, and BH4. The pro-apoptotic group of Bcl-2 
members can be divided into two subgroups: the Bax-subfamily consists of Bax, Bak, 
and Bad possess the domains BH1, BH2, and BH3, whereas the BH3-only proteins such 
as Bid, Bim, Bik, Bad, Bmf, NOXA, PUMA and Spike have only the short BH3 motif, 
an interaction domain that is both necessary and sufficient for their killing action (Haupt 
et al., 2003). 
 
 
 In mutagenesis studies, inactive Bcl-2 which undergoes mutation in the BH1 
domain which retains the BH3 domain, was unable to heterodimerize with the full-
length Bax, and hence cannot inhibit apoptosis.  
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However, the Bcl-2 can bind to the C-terminally condensed Bax with complete 
set of BH3 domain to induce apoptosis. It can be suggested that there are some 
conformation constraints in the full-length Bax that does not allow the binding of Bcl-2. 
It is demonstrated that the BH3 domain in Bax is responsible for the binding between 
Bax and Bcl-2. 
 
1.5.1 Regulation of Bcl-2 family members 
 
 
It is essential to maintain a proper balance and regulation between the anti-
apoptotic proteins and pro-apoptotic proteins, as improper regulation of expression of 
the apoptotic genes may affect the viability of normal cells, hence leading to the 
development of cancerous cells. The Bcl-2 family genes, including Bax, NOXA, PUMA 
and the most recently identified, Bid are p53 targets. Bax is a cytosolic monomer in 
viable cells but during apoptosis changes its conformation, integrates into the outer 
mitochondrial membrane and oligomerizes. Bax was the first member of this group 
shown to be induced by p53, but p53-responsive elements have only recently been 
clearly identified in the Bax gene (Thornborrow et al., 2002). In response to stress 
activation, Bax forms a homodimer and releases cytochrome c from the mitochondria 
(Skulachev, 1998), which results in caspase 9 activation (Cory and Adams, 2002). 
  
In contrast, anti-apoptotic Bcl-2 members seize pro-apoptotic Bcl-2 members by 
binding to their BH3 domains and prevent Bax or Bak activation or oligomerization and 
thus inhibit mitochondrial pro-apoptotic events where over expression of Bcl-2 or Bcl-
XL potently inhibits apoptosis (Figure 1.6). 
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Figure 1.6: Regulation of apoptosis by the Bcl-2 family. In a viable cell, the pro-apoptotic Bcl-2 
family members Bax, Bak, and BH3-only proteins are antagonized by anti-apoptotic members 
such as Bcl-2. In response to an apoptotic stimulus, BH3-only members are activated by 
transcriptional up-regulation (Bax, NOXA, and PUMA), sub-cellular relocalization (Bim, Bmf), 
dephosphorylation (Bad), or proteolysis (Bid). Activated BH3-only proteins prevent anti-
apoptotic Bcl-2 members from inhibiting pro-apoptotic members. In consequence, pro-apoptotic 
factors are released from the inner mitochondrial membrane into the cytosol, such as 
cytochrome c which contributes to the formation of the apoptosome and the subsequent 
activation of the caspase cascade. (Adapted from Apo Review: Introduction to Apoptosis. 
Gewies, 2003). 
 
 
 
Role of Bax in apoptosis induction has recently been offered in the context of 
PUMA. The PUMA gene is also directly induced by p53 in response to DNA damage, 
through p53-responsive elements within the first intron of PUMA. In humans, PUMA 
encodes two BH3-domain-containing proteins, PUMA-a and PUMA-b (Nakano and 
Vousden, 2001). A vital balance between PUMA and p21 has been identified to 
determine the onset of arrest, or death, in response to exogenous p53 expression. If p21 
is disrupted, the cells die through apoptosis and if PUMA is disrupted, apoptosis is 
prevented. Bax is absolutely required for PUMA-mediated apoptosis. PUMA expression 
promotes mitochondrial translocation and mulitmerisation of Bax, and ends in apoptosis 
induction (Yu et al., 2003). 
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Thus, although p53 can bind to the Bax promoter, the affinity is weak in contrast 
to p21 and PUMA binding. Bax thus participates in the death response as an indirect 
target of p53 through PUMA (Yu et al., 2003). Another p53 target gene, Noxa, contains 
a single p53-responsive element in its promoter and is induced in response to X-ray 
irradiation. Thus, in response to DNA damage, p53 activates the intrinsic mitochondrial 
apoptotic pathway by inducing the expression of at least three Bcl-2 pro-apoptotic 
family members, shifting the balance towards pro-apoptotic effects.  
 
1.6 p53 signalling pathways 
 Apoptosis is known as a major obstacle that must be overcome by tumour cells 
to allow them to survive and proliferate in such stressful conditions. Tumours obtain 
resistance to apoptosis through several strategies, frequently observed, for example the 
loss-of-function mutations of the phosphoprotein 53 (p53) tumour suppressor proteins. 
The tumour suppressor p53 is a transcription factor that has a critical role in preventing 
cancer. Since p53 can induce apoptosis by activating transcription of pro-apoptotic Bcl-
2 proteins in the circumstance of DNA damage, non-functional p53 can directly be 
linked to a failure to induce apoptosis after cellular stress (de Bruin et al., 2008) 
 Depending upon the stimulus and the state of the cell, activation of p53 can lead 
to either the halting of cellular proliferation and DNA repair, or induction of apoptosis. 
While the primary stimulus for activating p53 is DNA damage, other cellular stresses 
including metabolite deprivation, physical damage, heat shock, and loss of oxygen can 
also lead to p53 activation (Blatta and Glicka, 2001).  
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 Among the factors that activate p53 in the absence of DNA damage are 
expression of oncoproteins, non-genotoxic drugs, ribonucleotide pool depletion and 
hypoxia (Oleinik, 2005). 
 In a normal state, the cell has low levels of p53 because of the metabolic 
instability of inactivated p53. Phosphorylation takes place in order to activate p53 after 
DNA damage or cellular stress. A large number of kinases phosphorylate p53, including 
casein kinases, extracellular-signal-related kinases, JNK, protein kinase C, and Raf1 
kinase. However, the response to DNA damage is most likely mediated by DNA-PK (a 
caspase target), the product of the ataxia-telangiectasia gene (ATM), and the checkpoint 
kinase Chk2. The phosphorylation state of p53 is also controlled by the action of protein 
phosphatases 1 and 2A, in that inhibition of these enzymes by okadaic acid leads to 
phosphorylation of p53 (Blatta and Glicka, 2001). 
  Once phosphorylated, p53 then acts as a transcription factor to enhance and 
suppress the transcription of several genes involved in apoptosis. First, p53 increases 
the transcription of several genes that control the redox state of the cell. The synthesis 
of these genes leads to the production of reactive oxygen species that subsequently 
cause mitochondrial apoptosis.  
 p53 also up-regulates the transcription of Bax and suppress Bcl-2 transcription, 
altering the Bcl-2: Bax ratio which promotes apoptosis via a mitochondrial pathway . 
The Bcl-2 family of proteins direct mitochondrial membrane permeability and can be 
either pro-apoptotic or anti-apoptotic. 
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 It is thought that the main mechanism of action of the Bcl-2 family of proteins is 
the regulation of cytochrome c release from the mitochondria via modification of 
mitochondrial membrane permeability (Elmore, 2007). Besides p53 up-regulates the 
transcription of the Fas receptor which likely leads the cell to apoptosis induced by 
exposure to FasL.  
 Mutations in p53 have been shown to eliminate its functions in promoting 
apoptosis, cell-cycle arrest and DNA repair, thus leading to cancer development and 
progression. Activation of p53 results in the transactivation of many target genes that 
regulate these biological processes. Thus, loss of DNA-binding function of p53 results 
in amelioration of p53 dependent transcription, and hence, target genes required for the 
efficient execution of the biological processes are not activated. The significance of the 
DNA-binding property of p53 in regulating many of its biological functions is 
highlighted by the large percentage (~90%) of mutations found in DNA-binding domain 
(DBD) of p53 in human cancers (Vikhanskaya et  al., 2006). 
             p53 is also able to promote apoptosis through transcription-independent 
apoptotic mechanisms. Under certain conditions, p53 induces apoptosis in the absence 
of transcription or protein synthesis. Furthermore, transcriptionally inactive mutants of 
p53 can induce apoptosis in certain cell types and PIASg (protein inhibitor of activated 
STAT), which blocks binding of p53 to DNA, does not inhibit p53-mediated apoptosis.  
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 In general, the transcription independent apoptotic activities of p53 have been 
demonstrated in transformed cells rather than in normal cells (e.g. lymphocytes or 
fibroblasts). Apparently, these activities of p53 require cooperation with other apoptotic 
factors for instance E2F-1 (a transcription factor in the retinoblastoma protein pathway) 
(Haupt et al., 2003). 
 
1.7 Caspases  
 
 
 Caspases, or cysteine-aspartic proteases, are a family of cysteine proteases, 
which play essential roles in apoptosis (programmed cell death), necrosis and 
inflammation. Cell death classified to follow a classical apoptotic mode if execution of 
cell death is dependent on caspase activity. In the cell, caspases are synthesized as 
inactive zymogens procaspases, which at their N-terminus carry a prodomain, followed 
by a large and a small subunit which are sometimes separated by a linker peptide. Upon 
maturation, the procaspases are proteolytically processed between the large and small 
subunit, resulting in a small and a large subunit.   
Eleven caspases have so far been identified in humans. There are two types of 
apoptotic caspases, initiator caspases and executioner caspases. The pro-apoptotic 
caspases can be divided into the group of initiator caspases including procaspases 2, 8, 9 
and 10, and group of executioner caspases including procaspases 3, 6, and 7 (Earnshaw 
et al., 1999). 
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1.7.1 Caspase activation 
 
 
Caspases catalytical activity depends on a critical cysteine-residue within a 
highly conserved active-site pentapeptide - QACRG, and the caspases specifically 
cleave their substrates after Asp residues. So far, 7 different caspases have been 
identified in Drosophila, and 14 different members of the caspase-family have been 
described in mammals, with caspases 11 and 12 only identified in the mouse (Denault, 
2002).  
 
Caspases 1, 4, 5, 11 and 12 appear to be mainly involved in the proteolytic 
maturation of pro-inflammatory cytokines such as pro-IL-1ß and pro-IL-18 and their 
contribution to the execution of apoptosis remains questionable (Denault, 2002). 
Caspases 9 and 2 respond to changes in mitochondrial potential, whereas caspases 8 and 
10 sense activation of death receptors. These initiator caspases cleave the pro-enzyme 
forms of the effector caspases 3, 6 and 7, allowing digestion of essential targets that 
affect cell viability (MacLachlan and El-Deiry, 2002). 
 
Caspases 2, 3, 6, 7, 8, 9 and 10 have been recognized to play important roles in 
the apoptotic signalling machinery (Earnshaw et al., 1999). p53 can activate the caspase 
cascade by both transcriptions of the dependent and independent mechanisms. In 
response to g-irradiation, p53 can activate caspase 8 (Ding et al., 1998).  
 
 
 
 
 
 25 
 
p53 also stimulates caspase 6 through a more conventional mechanism. In 
response to DNA damage, p53 directly induces caspase 6 expression through a response 
element within the third intron of the gene (MacLachlan and El-Deiry, 2002). Caspase 6 
cleaves the nuclear envelope protein lamin A and several transcription factors (Galande 
et al., 2001). Caspase 6 plays an important role in p53 induced neuronal cell death and 
is the major protein involved in the cleavage of the amyloid precursor protein (LeBlanc 
et al., 1999).  
 
1.8 Treatments of cancer 
 
Treatment for cancer can be localised, where the cancer cells in the tumour and 
the surrounding area is being directly targeted by chemotherapy and immunotherapy or 
systemic, where the treatment drugs will travel through the bloodstream and reach 
cancer cells all over the body such as hormone therapy.  
 
Surgery or drug treatments are the primary treatment for many solid tumours. 
Benign growth or early detected cancer can be cured by surgery by removing all 
cancerous cells and in combination with radiation to completely kill any remaining 
cancer cells directly by damaging them with high energy beams. Radiation can be either 
external or internal. In the external form, the radiation comes from a machine that aims 
the rays at the tumour. In internal radiation, radioactive material is sealed in needles, 
seeds, or wires and placed directly in or near the tumour. 
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Chemotherapy is a word used for a wide array of drugs used to kill cancer 
cells. Chemotherapy drugs work by damaging the dividing cancer cells and preventing 
their further replication without killing normal host cells and tissues. Primary 
chemotherapy or neoadjuvant chemotherapy is a chemotherapy used before surgery. 
The purpose of this chemotherapy is to reduce the size of the tumour. The more 
common use of chemotherapy is adjuvant therapy. In this treatment, chemotherapy is 
given after surgery to destroy any remaining cancer cells and prevent cancer from 
persisting. Chemotherapy is also used in conjunction with radiation therapy. 
 
In hormonal treatments, the drugs are designed to prevent cancer cell growth by 
preventing the cells from receiving signals essential for their continued growth and 
division. Thus the growth of the tumour slows and survival may be extended for several 
months or years.  
 
Antibodies are also used to target cancer cells. Specific inhibitors are quite new 
in the treatment of cancer. The antibodies work by several different mechanisms, either 
depriving the cancer cells of necessary signals or causing the direct death of the cells. 
As a result of their specificity, antibodies are considered as a type specific inhibitor. 
They target specific proteins that primarily promote growth of cancer cells. Inhibition of 
these processes prevents cancer cell growth and division. 
 
  High intensity focused ultrasound (HIFU) is also found to be the current 
treatment for cancer. It is a highly precise medical procedure using high-intensity 
focused ultrasound to heat and destroy tumour tissues rapidly. 
 
 
 27 
 
The use of vaccines is also important in cancer treatment. Cancer vaccines are to 
stimulate the body's defences against cancer. Vaccines usually contain proteins or 
antigens found on or produced by cancer cells. Administration of these proteins aims to 
increase the immune response of the body against the cancer cells, especially in 
enhancing the cytotoxic T (TC) and natural killer (NK) cells responses. 
 
 
1.8.1 p53-mediated cancer therapy 
 
 
Stimulation of disabled p53 pathways has been suggested as a potential mode 
for cancer therapy. Potential approaches include introducing wild-type p53 genetically, 
allowing abnormal p53 molecules to perform wild type functions, or intervening to 
activate directly targets in the p53 apoptotic pathways. Gene therapy based on the 
introduction of wild-type p53 (Wen et al., 2003) and elimination of mutant p53- 
expressing cells is undergoing clinical trials. Restoration of wild-type conformation to 
structurally distorted p53 DNA-binding mutants has been demonstrated by using 
peptide constructs and small molecular weight synthetic molecules. Synthetic peptides 
derived from the C-terminus of p53 can induce p53-dependent apoptosis in tumour cells 
and restore the specific DNA-binding and transcription functions to mutant p53 in vitro 
(Selivanova et al., 1999).  
 
In vivo activity of these peptides has been associated with an increase in the 
levels of the Fas receptor on the cell surface, through a p53-dependent mechanism. 
(Kim et al., 1999). Other small synthetic peptides derived from a p53- binding protein 
have been introduced to restore sequence specific DNA-binding activity to mutant p53 
(Friedler et al., 2002).  
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p53 reactivation and induction of massive apoptosis (PRIMA) is a small 
molecular weight molecule that provokes apoptosis in a transcription-dependent manner 
through conformational manipulation of p53 mutants to restore sequence-specific DNA 
binding (Bykov et al., 2002). CP-31398 is another small synthetic molecule with the 
capacity to restore wild-type p53 function by inducing apoptosis or growth arrest 
induction. CP-31398 has been suggested to trigger apoptosis through the intrinsic 
pathway by increasing DR5 cell surface exposure and reduction in p53-ubiquitination 
with this molecule (Wang et al., 2003). 
 
1.8.2 ELISA and p53 tumour suppressor gene 
 An early event in apoptosis is DNA fragmentation and release of nucleosomes 
into the cytoplasm (Salgame et al., 1997). An enzyme-linked immunosorbent assay 
(ELISA) for apoptosis is based upon the detection of cytoplasmic nucleosomes. The 
nucleosome is the basic unit of chromatin and results from the ordered association of 
histones and DNA. The double antibody sandwich ELISA is based upon the specific 
recognition of nucleosomes by a pair of monoclonal antibodies (mAb).  
 Nucleosomes in cytoplasmic lysates are captured onto ELISA plates coated with 
a first mAb reacting with an exposed epitope of histone H2B. The bound nucleosomes 
are then detected by a second mAb specific for the complex formed by the H2A–H2B 
dimer and DNA. ELISA could detect as low a number of apoptotic cells as possible. 
ELISA is easy to perform, extremely sensitive, and particularly suited to detect 
apoptosis in a large number of samples (Salgame et al., 1997). 
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 ELISA has been widely employed to measure p53 levels, for example in 
determining the amount of p53 in tumour tissues and in the nervous system, as well as 
for detecting p53 mutants. ELISA analysis has also been used to detect and quantitate 
auto-antibodies against mutant p53 in cancer patients. ELISA also used to identify 
p53/DNA complex formation due to role of p53 and DNA binding properties. The 
results indicate that detection of p53/DNA binding properties opens new possibilities 
for analyzing the function of p53 in a wide variety of circumstances (Jagelska et al., 
2002). 
1.8.3 Current efforts in improvement of cancer treatments 
 
 Although many treatments are currently used in treating cancer, some of them 
still have several limitations. In chemotherapy and radiation therapy, the selected target 
cells that are in the process of proliferation; both malignant and non malignant cells are 
subject to cytotoxic or immunotherapeutic effects.  
 
 Researchers have been able to create new targeted therapies for cancer treatment 
to minimize the harmful effects of therapy on healthy cells through new understandings 
and theories of how cancer cells survive, and metastasize cancer therapy may be more 
effective if the proteins associated with the specific pathways  such as cell membrane 
receptors, signalling pathways, enzymatic activity, and regulatory cell growth controls  
for cancer transformation and progression are interrupted or blocked within the cell’s 
macro-environment. 
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 The benefits of more selective agents include a higher therapeutic index and a 
lower toxicity profile than conventional therapy. In chemotherapy, their toxicity is not 
limited to cancer cells only, but the normal cells are also harmed. Cancer cells are 
difficult to target because they are so similar to normal cells. Both proliferate using the 
same cellular machinery, and destroying that machinery in one destroys it in the other. 
Rapidly dividing cells are particularly affected because their high proliferation rate 
makes them dependent on frequent DNA synthesis. Thus chemotherapy has been highly 
successful on fast-growing cancers such as testicular cancer and some forms of 
leukemia.  
 
 Chemotherapy is not considered remedial although it can induce complete 
responses because treated patients will generally develop recurrent disease requiring 
additional therapy which can cause worsening immune dysfunction. A modified form of 
chemotherapy, isolated limb perfusion, is being studied as an alternative to traditional 
chemotherapy when the melanoma occurs on an arm or leg. Isolated limb perfusion 
involves temporarily stopping the flow of blood to the affected limb with a tourniquet 
and administering a high dose of chemotherapeutic medication to the affected area. It is 
believed that high doses can more effectively destroy the cancerous cells. This has been 
beneficial for some patients. 
 
 Vascular endothelial growth factor (VEGF) has emerged as a key target for the 
treatment of cancer. As the ligand to the VEGF receptor, it plays a central role in 
promoting tumour angiogenesis. Over-expression of VEGF leads to poor outcomes in 
patients with breast cancer and other tumours.  
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 Preclinical studies have shown that the humanized monoclonal antibody to 
VEGF, bevacizumab can reduce tumour angiogenesis and inhibit the growth of solid 
tumours, either alone or in combination with chemotherapy. 
 
1.9 Natural compounds and cancer 
 
Natural compounds are being investigated extensively worldwide as potential 
anti-cancer agents. 48 of 65 the drugs (74%) that were approved for cancer treatment 
have been extracted from natural sources, and created by structural modification, or by 
the synthesis of new compounds, designed following a natural compound as model 
(Gordaliza, 2007). Most of these natural anticancer agents available today are derived 
from plants, animals, marine organisms and microorganisms. Some currently used 
examples of plant-derived compounds are vincristine, irinotecan, etoposide and 
paclitaxel, while bleomycin and doxorubicin are microbial-derived compounds and 
citarabine, derived from a marine source (da Rocha et al., 2001).  
 
Limonoids are unique highly oxygenated triterpenoid compounds long 
recognized as significant biologically active natural compounds. Citrus limonoids 
appear in large amounts in citrus juice and citrus tissues as water soluble limonoid 
glucosides or in seeds as water insoluble limonoid aglycones (Ozaki et al., 1995). Over 
300 limonoids have been isolated to date. Past work has established a wide range of 
biological activities for these compounds including insect antifeedant and growth 
inhibiting characteristics.  
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Although best known for their insecticidal properties a variety of medicinal 
effects in animals and humans has been illustrated including some anti-carcinogenic 
effects on in-vitro human tumour cell lines and test animals.  
 
 
Other limonoid properties include antifungal, bactericidal, and antiviral effects. 
Extracts of many citrus species are used traditionally in the herbal medicines of the Far 
East.  The fruits and bark of the Chinaberry (Melia azedirach) have been used as a 
treatment for a variety of ailments in small doses, as it can be toxic to humans. Some of 
the most exciting applications of limonoids and compounds derived from them are their 
use in the treatments of specific cancers. Limonin, nomilin, 12- hydroxyamdorastatin, 
and isofraxinellone are limonoids or their derivatives that have been shown successful 
in treatments with in vitro bioassays on human tumour cell lines (Bagge, 2008). 
 
Several citrus limonoids have recently been subjected to anti-cancer screen 
procedures utilizing laboratory animals and human breast cancer cells in culture. In 
mice, it was found that five limonoid aglycones (limonin, nomilin, obacunone, 
isoobacunoic acid) induced significant amounts of glutathione-S-transferase (GST) in 
the liver and intestinal mucosa (Lam and Hasegawa  et al., 1994). GST is a major 
detoxifying enzyme system which catalyzes the conjugation of glutathione with many 
potentially carcinogenic compounds which are highly electrophilic in nature. 
 
Most recently, several limonoid aglycones and a mixture of limonoid glucosides 
were administered in vitro to estrogen dependent and estrogen independent human 
breast tumour cell lines (Guthrie et al., 2000).  
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The results showed that the limonoids were equally potent as tamoxifen for 
inhibiting the proliferation of estrogen dependent breast cancer cells, and more effective 
than tamoxifen for activity against estrogen-independent cancer cells. Limonin and 
obacunone fed to rats have also been shown to increase GST and quinine reductase 
activities in liver and colon mucosa and was correlated with the prevention of colon 
carcinogenesis in rats (Tanaka et al., 1999). 
 
 The insecticidal properties of many limonoids, especially C-seco, and many 
more widely distributed intact apo-euphol skeleton, 14,15- epoxide limonoids, are 
driving many recent studies in the extraction and isolation of these compounds from 
new sources due to continued exposition of limonoid compounds against organisms 
other than insects. Indications of the antifungal, bacteriacidal, protisticidal and antiviral 
characteristics suggest a broader role for these compounds. With over 300 similar 
compounds, the bioassay of known limonoids for their anticancer and anti-mutagenic 
activities will promote much more investigation for cancer treatment. 
 
 
1.9.1 Erythrocarpine E (CEB4) - a novel natural compound from Chisocheton 
erythrocarpus  
 
 
 
 Erythrocarpine E (CEB4) is a new cytotoxic limonoid which is dichloromethane 
extracted from the bark of Chisocheton erythrocarpus Hiern from Meliaceae family. 
This newly extracted limonoid have been shown to have cytotoxic activity against P-
388 murine leukemia cells at IC50 of 18µg/ml. It is a A, B, D-seco heptacyclic limonoid 
having mexicanolide type skeleton with cinnamoyl group as side chains at C-3 (Awang 
et al., 2007). CEB4 with a molecular formula of C36H38O9 with the presence of 
functionalities such as a b-furyl ring, a methoxy group, a conjugated d-lactone ring, and  
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a cinnamoyl group. The Me-29 was suggested to be oxidized and cyclized with C-1 to 
form an oxygen-bridge in the ring A. It is different to the typical 4, 29, 1-carbon-bridge 
sequence found in the phragmalin skeleton which was biogenetically and structurally 
closely related to mexicanolide skeleton (Awang et al., 2007). The structure of CEB 4 is 
shown below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Structure of erythrocarpine E (CEB4) 
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1.9.2 Objectives of the study: 
 
 
 Erythrocarpine E (CEB4), extracted from Chisocheton erythrocarpus Hiern is 
being investigated as a potential natural compound to induce apoptosis in tumour cell 
lines. Therefore, this study was carried out with the aim: 
 
 
1. To investigate effects of CEB4 on cell viability using MTT assay and 
fluorescence microscopy. 
 
2. To investigate effects of CEB4 on cell cycle progression and apoptosis using 
flow cytometry. 
 
3. To assess whether CEB4 treatment of cancer elicits an apoptotic response, using 
Western blot analysis of PARP cleavage and DNA fragmentation analysis. 
 
4. To determine if p53 and its associated regulatory proteins function to elicit the 
apoptotic response observed following CEB4 treatment of cancer cells. 
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CHAPTER 2.0: MATERIALS AND METHODS 
 
2.1 Materials and methods of CEB4 compound 
 
2.1.1 Plant material:  
Chisocheton erythrocarpus Hiern was collected from Hutan Simpan Terenas, 
Kedah, Malaysia. Voucher specimens (KL 4863) were deposited in the Herbarium of 
Chemistry Department, University of Malaya. 
 
2.1.2 Botanical Aspect of Chisocheton erythrocarpus Hiern  
 
 This plant is commonly known as Rongga in Malaysia. It is a big tree that can 
grow up to 80 feet tall with the branchlets velvety tomentose. Its leaves are 12 to 15 
inches long with 4-6 pairs of coriaceous elliptic-oblong or broad ovate leaflets. The 
flowers are about 0.35 inches long with its petals elliptic silky outside and stamen-tube 
shorter silky below. The seeds are ex-arillate to about 1 inch and are orange red in 
colour. 
 
 
2.1.3 Extraction and isolation 
 
 
 Dried ground barks (1.3kg) were extracted successively with hexane, 
dichloromethane, and methanol. The dichloromethane extract (4.7g) was repeatedly 
subjected to silica gel column chromatography using solvent mixture of hexane: ethyl 
acetate (7:3) and final purification was done by PTLC using the same solvent system. 
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Erythrocarpine E 
[α]D: -128° (c 0.8, CHCl3) 
 
IR (KBr): 3413, 2928, 1700, 1201 cm-1 
UV/Vis λmax (MeOH): 297 nm 
1H NMR (400 MHz, CDCl3): 2.95 (1H, dd, J=7.1, 10.1 Hz, H-2), 4.91 (1H, d, J=10.1 
Hz, H-3), 2.92 (1H, m, H-5), 2.31 (2H, m, H-6), 2.34 (1H, dd, J=3.2, 10.2 Hz, H-9), 
1.54 (1H, m, H-11), 1.68 (1H, m, H-11), 1.17 (1H, m, H-12), 1.89 (1H, m, H-12), 2.76 
(2H, dd, J=18.1, 18.1 Hz, H-15), 5.46 (1H, s, H-17), 0.88 (3H, s, Me-18), 1.02 (3H, s, 
Me-19), 7.64 (1H, s, H-21), 6.29 (1H, br s, H-22), 7.30 (1H, d, J=1.5 Hz, H-23), 0.62 
(3H, s, Me-28), 3.46 (1H, d, J=9.3 Hz, H-29), 3.88 (1H, d, J=9.3 Hz, H-29), 5.53 (1H, 
dd, J=1.7, 7.1 Hz, H-30), 3.65 (3H, s, 7-Ome), 6.25 (1H, d, J=15.7 Hz, H-2’), 7.58 (1H, 
d, J=15.7 Hz, H-3’), 7.19 (1H, m, H-5’), 7.18 (1H, m, H-6’), 7.19 (1H, m, H-7’), 7.18 
(1H, m, H-8’), 7.19 (1H, m, H-9’). 
 
13C NMR (90 MHz, CDCl3): 97.3 (C-1), 44.8 (C-2), 74.9 (C-3), 36.2 (C-4), 34.9 (C-5), 
31.7 (C-6), 174.0 (C-7), 140.5 (C-8), 43.6 (C-9), 41.4 (C-10), 19.0 (C-11), 28.2 (C-12), 
41.2 (C-13), 78.9 (C-14), 39.4 (C-15), 168.8 (C-16), 76.9 (C-17), 14.8 (C-18), 14.7 (C-
19), 120.3 (C-20), 146.2 (C-21), 109.8 (C-22), 142.6 (C-23), 15.5 (C-28), 67.9 (C-29), 
122.1 (C-30), 52.1 (7-Ome), 166.4 (C-1’), 117.0 (C-2’), 146.2 (C-3’), 134.4 (C-4’), 
128.3 (C-5’), 128.5 (C-6’), 129.9 (C-7’), 128.5 (C-8’), 128.3 (C-9’). 
HRMS-FAB: m/z [M + H+] = 633.3703 
 
 
 
2.2 Cell lines and culture conditions 
 
 
Human epidermoid cervical carcinoma cells (CaSki) and human hepatocyte liver 
carcinoma (HepG2) cells were obtained from Medical Faculty of University of Malaya. 
Human breast adenocarcinoma cells (MCF7), human oral squamous carcinoma cells 
(HSC2 and HSC4COX2-) were obtained from Cancer Research Initiative Foundation, 
Subang Jaya Medical Center (CARIF, SJMC). Normal human bronchial epithelial cells 
(NHBE) were obtained from Cancer Research Initiative Foundation, Subang Jaya 
Medical Center (CARIF, SJMC). 
 
  CaSki, HepG2, HSC2 and HSC4COX2- cells lines are culture flask attached cells 
and were grown in Dulbeco’s Modified Eagle Medium (DMEM) (Lonza, USA) culture  
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media while the MCF7 cells were cultured in Roswell Park Memorial Institute 1640 
medium (RPMI 1640). Heat activated 10% (v/v) fetal bovine serum (Lonza,USA) that 
contains a rich variety of protein was added to the culture media to maintain growth of 
the cells. The NHBE were cultured with Bronchial Epithelial Basal Medium (BEBM) 
with 10% FBS and 1% penicillin/ streptomycin.  
 
 Cancer cells were plated on a 25.0 cm2 culture plate (Nunc, Denmark) and 
incubated in a carbon dioxide (CO2) incubator (Memmert, Gemany) with high relative 
humidity (95%) , stable temperature (37ºC), controlled CO2 levels (5%)  and controlled 
pH (7.2-7.4). Culture media had buffer system that contained appropriate amount of 
bicarbonate where 5% atmosphere CO2 levels helped maintain culture media in a proper 
pH (7.0 to 7.6).  These essential variables create an ambient environment for 
mammalian cells to thrive. Culture media were also supplemented with 100 units/mL 
penicillin or streptomycin (Lonza, USA) to prevent growth of bacteria and do not have 
an adverse effect on the viability of cells. 
 
2.2.1 Subculturing and maintenance of adherent cell lines 
 
 
 The culture medium of the cell lines grown in 25.0 cm2 filter cap culture flask 
(Nunc, Denmark) was removed and discarded using an aspirator. The cell monolayer 
was then rinsed with sterile autoclaved 1X Phosphate Buffer Saline (PBS) (Lonza, 
USA) to wash off any remaining culture medium. The solution in the culture flask was 
removed and discarded using an aspirator. Next, 3.0 ml of dissociating agent 0.25% 
trypsin (Lonza, USA) was added to the culture flask. The culture flask was then 
incubated at 37°C in 5% CO2 incubator (described in 2.2) for approximately 10 minutes 
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to allow the cells in the culture flask to detach. The progress of cell detachment was 
checked every 5 minutes using an inverted microscope (Labscope, China). 
 
 
 Then 3.0 ml of the appropriate growth medium was added to the culture flask. 
Any remaining cells were washed from the bottom of the culture flask and a quick 
check was done under the inverted microscope to look for single cells in the suspension. 
If they were not mostly single cells, more vigorous pipetting was done on the 
suspension. All the suspension from the culture flask was then transferred to a labeled 
15.0 ml Falcon tube and the tube was centrifuged for 10 minutes at 1500 RPM using 
Centrifuge 5702 (Eppendorf, USA). The supernatant in the tube was then discarded and 
the pellet was resuspended in 4.0 ml to 6.0 ml of the appropriate growth medium. The 
cell suspension was then collected for counting or passaging into prepared culture 
flasks. 
  
2.2.3 Cell count 
 
 
The cell suspension was gently mixed and a 20.0 µl of the suspension was 
aliqouted into a 1.5 ml microcentrifuge tube and 20.0 µl of trypan blue (Sigma Aldrich, 
USA) stain was then added to this aliquot and mixed well. The tube was allowed to 
stand for about 3 minutes. After 3 minutes, 10.0 µl of the mixture was then removed and 
loaded on a clean hemacytometer (Germany) to be counted. The counting was done 
under an inverted microscope. Dead cells will be seen as blue while viable cells will be 
seen as bright spheres. 
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 The counting was done and the actual concentration of the cell suspension 
(number of cells/ml) was calculated according to the formula: 
 
 
 
 From the concentration, the volume of suspension required for cell plating was 
calculated. Approximately 1.0 x 104of cell suspension was then transferred to a new 
25cm2 culture flask with 3.0 ml of new growth medium being added and the culture 
flask was then stored for routine maintenance of cell lines in 37°C and 5% CO2 . 
 
2.3 Cytotoxicity and viability assay 
 
 
2.3.1 MTT assay 
 
 A cytotoxicity assay of CEB4 isolated by Chemistry Department of University 
Malaya was done on normal cell line and five cancer cell lines. Cells at a volume of 
100.0µl/well were plated on a 96-well plate (Nunc, Denmark). The maximum density 
for each well was about 1.0 x 104 cells with culture medium and cell based controls. 
Cells were incubated for a period of 24 hours to allow for reattachment to the wells. All 
of the experiments were plated in triplicates and the results of the assays were presented 
as means ± SD. 
 
 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution 
was prepared by adding 50.0 mg of MTT (Merck, Germany) to 10.0 ml of 1X PBS in a 
15 ml tube. The solution was stored at 2 to 8°C in the dark until further use. 
(Total number of cells counted)(Dilution factor) 
(Proportion of chamber counted)(Volume of chamber) 
X 1000 
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 The solution of the compound CEB4 was prepared by adding dimethyl sulfoxide 
(DMSO) (Merck, Germany). The concentration of stock solution of CEB4 is 10.0mM 
and the concentration of working solution of CEB4 is 1.0mM. After 24 hours the cells 
were treated with the CEB4 at different concentrations of 0.0, 5.0, 10.0, 20.0, 30.0, and 
40.0 µM (working solution)  for 6, 12, 18 and 24 hours for each concentration of CEB4. 
10.0 µl of MTT solution was added to each well at the end of each incubation time point 
and was mixed by gently tapping the plates and incubated for approximately 2 hours at 
37°C.  
 After the incubation hours, the media was removed and 200.0 µl of DMSO was 
added to each well and the plates were left to incubate overnight to allow the formazan 
crystals to dissolve. Once the crystals were dissolved, the absorbance values of the wells 
were measured using Sunrise microplate reader (Tecan, Switzerland) at 570 nm 
wavelength.   
 
 
2.3.2 Live and dead assay 
 
 
  The objective of this assay is to observe cell-mediated cytotoxicity. The 
cytotoxicity result would give a visual confirmation of the MTT assay results. We used 
a LIVE/DEAD® Viability/Cytotoxicity Kit  which determines intracellular esterase 
activity and plasma membrane integrity. This assay uses calcein, a polyanionic, green 
fluorescent dye that is retained within live cells, and a red fluorescent ethidium bromide 
homodimer dye that can enter cells through damaged membranes and bind to nucleic 
acids but is excluded by the intact plasma membranes of live cells. In brief, cells (1.0 × 
105 per well) were incubated in 12-well plates, treated with CEB4 for 12 hours using 
IC50 values of each cell lines and then stained with the assay reagents for 30 minutes at 
ambient temperature. Cell viability was observed under a fluorescence microscope. 
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2.4 Flow cytometry analysis 
 
 
2.4.1 Cell cycle analysis 
 
  
 Cell cycle analysis was performed using PI based staining methods. CEB4 
treated and untreated cells were fixed in ice-cold 70% (v/v) ethanol and kept at -30°C. 
Staining of nuclear DNA content was conducted by adding PI (50.0g/ml) and RNase A 
(10.0mg/ml), followed by incubation at 37°C for 30 minutes in the dark. Fluorescence 
from a population of 1.0 x 104 cells was detected using a flow cytometer (BD 
FACSCaliburTM, USA) at 488 nm wavelength. 
 
2.4.2 Annexin V assay 
 
The objective of this analysis is to determine whether the cytotoxic effect in the 
MTT assay is apoptotic. Detection of apoptosis was conducted using the Annexin V-
FITC/PI apoptosis detection kit. Briefly, both CEB4 treated and untreated cells were 
harvested by trypsinization, washed in PBS  and stained with annexin-V FITC 
conjugate and PI  according to the manufacturer’s protocol (Calbiochem ,Merck). Cells 
(1.0 x 104) were then analyzed by flow cytometry (BD FACSCaliburTM, USA) using 
BD CellQuest acquisition and analysis software.  
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2.5 DNA fragmentation assay 
 
 Total DNA was extracted from both untreated cells and cells treated with CEB4 
for 12hours and 24 hours using the Suicide Track TM DNA Ladder Isolation Kit 
according to the manufacturer’s protocol. Isolated DNA was analysed on a 1.0% 
agarose gel electrophoresis and stained with ethidium bromide. Fragmentation of DNA 
was observed under UV illumination and visualized using a gel documentation system 
(Alpha Inotech, USA) 
 
 
2.6 Sandwich ELISA assay 
 
 
The cells were both grown in a two 20.0cm2 culture plate separately (Nunc, 
Denmark) in CO2 incubator until reached 80 % confluency. The confluency of cells on 
culture plate was verified using an inverted microscope (Labscope, China). Culture 
plates were then washed with autoclaved sterile 1 X PBS (Lonza, USA). New culture 
DMEM medium was added to the cell plates. Two of the cell culture plates were treated 
with CEB4 according to IC50 value (Table 2.2) and incubated in CO2 incubator 
(Memmert, Germany) for 6 and 12 hours separately. Another cell culture plate was not 
treated with any CEB4 and act as a control. Cell lysates were harvested according to the 
manufacturer’s protocol (Cell Signalling Technology, USA). The relative percentage of 
phosphorylated p53 at each time point was calculated according to the formula: 
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2.7 PARP cleavage and expression of p53 and other p53 signalling related 
      apoptotic proteins by Western analysis 
 
 Cancer cells were grown in a 10.0 cm2 dish, until cell density reached 80% 
confluency. The CEB4 treated cells were then washed once with ice-cold PBS and NE-
PER® Nuclear and Cytoplasmic Extraction Kit (Pierce, USA) was used to extract 
nuclear and cytoplasmic proteins separately instead of whole cell lysates. The protein 
concentration was determined by the Bio- Rad DC protein assay (Bio-Rad Laboratories, 
USA). Equal amounts of protein (20.0 mg/lane) were subjected to 12% SDS-PAGE and 
transferred to a nitrocellulose membrane.  
 
 The membranes were subsequently incubated with the corresponding primary 
antibodies, as indicated: Equal amount of cytoplasmic and nuclear extracts of each cell 
lines was probed against 9 antibodies: β-actin, PARP, p53, phospho-p53, Bax, Bcl-2, 
MDM2, caspase 3, Caspase 9 antibodies (Cell Signalling Technology) were probed with 
for 1 hour at room temperature.  
  
 After extensive washing in TBST buffer, respective secondary antibody, anti-
rabbit IgG antibodies linked to horseradish peroxidase (Zymed Laboratories Inc, CA) 
was added with the blocking buffer for another 1 hour. Antibody bound proteins were 
detected by the ECL western blotting analysis system (Amersham Pharmacia Biotech 
UK Limited). 
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CHAPTER 3.0: RESULTS 
3.1 MTT viability assay 
 
 The objective of these MTT assays was to assess cytotoxicity of CEB4 on the 
five human cancer cell lines and normal cell line and to determine the inhibition 
concentration (IC50) of CEB4 on these human cancer cell lines. MTT assays were 
performed in time and dose dependent manner on oral (HSC4COX2- and HSC2), cervical 
(CaSki), breast (MCF7), liver (HepG2) and normal human bronchial epithelial (NHBE) 
cell lines, which acted as positive control throughout this study. 
 
 It was also of interest to investigate on which of the five different cancer cell 
lines (available in the laboratory) that CEB4 has the strongest cytotoxic effect. Results 
(figure 3.1 a-b) indicated that CEB4 induced cytotoxicity on the treated cancer cells in a 
dose and time dependent manner. CEB4 also shows minimal cytotoxicity effect on 
NHBE.  
 
 
Figure 3.1(a): Dose-dependent MTT assay graph. Comparison of total relative cell viability (%) 
between various cancer cell lines and normal cell line (NHBE) after treatment with CEB4 at 24 
hours with different concentrations (0 to 40.0µM). Results were expressed as total percentage of 
viable cells. Each value is the mean ±SD of three determinations.    
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Figure 3.1(b): Time-dependent MTT assay graph. Comparison of total cell viability (%) 
between various tumour cell lines and normal cell line (NHBE) after treatment with 40.0µM of 
CEB4 at 0, 6, 12 and 24 hours. Results were expressed as total percentage of viable cells. Each 
value is the mean ±SD of three determinations.  
 
 
 Figure 3.1(a) shows percentage of total viable cancer cells of HSC4COX2- HSC2, 
CaSki, HepG2 and MCF7 and normal cell line, NHBE, against CEB4 concentration at 
5.0, 10.0, 20.0, 30.0, 40.0 µM at 24 hours incubation. Percentage of viable cancer cells 
decrease after 24 hours treatment. The sensitivity of the cancer cell line can be observed 
in ascending order: HepG2, MCF7, CaSki, HSC2 and highest levels of cytotoxicity 
were observed in oral squamous carcinoma cells, HSC4COX2-. The result shows that 
CEB4 has cytotoxic effect on all five human cancer cells lines, affecting the percentage 
of total viable cells in a dose dependent manner.  
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 Figure 3.1(b) shows percentage of  total viable CEB4 treated cancer cells of  
HSC4COX2-, HSC2, CaSki, HepG2 and MCF7 decreasing at a concentration of 40µM at 
6, 12, 18 hours and at 24 hours incubation almost 100% killing was achieved. The 
highest degree of killing was observed in HSC4COX2-. The results demonstrated that the 
cytotoxic effects of CEB4 on all five human cancer cell lines were also time dependent. 
Viability of all cancer cells reduced and reaches only 50% at 12 hours as incubation 
concentration at 50% (IC50) were taken at 12 hours.  
Table 3.1: The IC50 value for each cancer cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore further experiments were conducted using IC50 value as shown in 
table 3.1 to treat all the cancer cell lines respectively. Minimal cytotoxic effect of CEB4 
was observed on NHBE cells where approximately 80.0% cell viability after 24 hours 
of incubation at 40.0µM. This reinforces that cytotoxic effect of CEB4 was only on 
cancer cells. Viability of cells treated with DMSO without CEB4 insignificantly 
affected (<1.0 %) (data not shown), indicating that cytotoxicity was induced by CEB4 
and not the solvent used to dissolve the compound. Both time and dose dependent 
Cell lines IC50 (µM) 
HSC4(COX2-) 18 
HSC2 20 
Caski 25 
HepG2 30 
MCF7 26  
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assays supported the need to further investigate the apoptotic effects of CEB4 and its 
potential as an anti-cancer drug for the treatment of cancer. 
 
 
3.2 Live and dead assay    
 
The objective of this assay was to observe cell-mediated cytotoxicity. The 
cytotoxicity result would give a visual confirmation of the MTT assay results. Live and 
dead assay was performed by using LIVE/DEAD® Viability/Cytotoxicity Assay Kit to 
observe viability and cytotoxicity of untreated and CEB4 treated of cancer cells and 
NHBE respectively. This kit provides a two-colour fluorescence cell viability assay that 
is based on the simultaneous determination of live and dead cells with two probes that 
measure recognized parameters of cell viability - intracellular esterase activity and 
plasma membrane integrity. 
 
The figure 3.2 shows the untreated cells and treated cells after treatment with 
CEB4 at 12 hours using dyes that recognized parameters of cell viability – intracellular 
esterase activity and plasma membrane integrity. Calcein AM (green dye) stains live 
cells while ethidium homodimer (red dye) stains dead cells. 
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Figure 3.2: Detection of cytotoxicity by using The LIVE/DEAD® Viability/Cytotoxicity Assay 
Kit on NHBE (Magnification X 300), HSC4COX2-, HSC2, CaSki, HepG2 and MCF7 
(Magnification X 500). 
 
 
The five CEB4 treated cancer cell lines were observed under fluorescence 
microscope and cell death was observed in all the cell lines. The control experiment 
with the normal cells, NHBE, showed no killing after treatment with CEB4. Therefore 
the result of this assay gives a visual confirmation of the MTT assay. 
 
 
 
3.3 Measurement of cell cycle by flow cytometry analysis 
 
 
 CEB4 treated and untreated cancer cells and NHBE cells were stained separately 
with propidium iodide and the DNA contents were analyzed by flow cytometry to 
compare cell cycle progression before and after CEB4 treatment. All the five cancer cell 
lines; HSC4COX2-, HSC2, CaSki, HepG2 and MCF7 were treated with CEB4 at their 
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respective IC50 value at 12 hours incubation. Only HSC4COX2-, CaSki, HepG2 and 
MCF7 except in HSC2 cells (figure 3.3 f) showed cell cycle progression as 
demonstrated in the flow cytometry analysis (figures 3.3 b-e), respectively. There were 
no changes observed in the normal cell line NHBE (figure 3.3 a). 
 
 
                                   
 
 
Figure 3.3(a): Cell cycle distribution of NHBE using flow cytometry after staining with 
propidium iodide (PI) before and after CEB4 treatment for 12 hours. I: Sub-G1; II: G0/G1; III: S; 
IV: G2/M. All experiments are a representative of a 10000 cell population and mean values of 
three independent replicates are plotted (n=3). The percentage of cells in all cell cycle phases is 
indicated. 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.3(b): Cell cycle distribution of HSC4COX2- using flow cytometry after staining with 
propidium iodide (PI) before and after CEB4 treatment for 12 hours. I: Sub-G1; II: G0/G1; III: S; 
IV: G2/M. All experiments are a representative of a 10000 cell population and mean values of 
three independent replicates are plotted (n=3). The percentage of cells in all cell cycle phases is 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.3(c): Cell cycle distribution of CaSki using flow cytometry after staining with 
propidium iodide (PI) before and after CEB4 treatment for 12 hours. I: Sub-G1; II: G0/G1; III: S; 
IV: G2/M. All experiments are a representative of a 10000 cell population and mean values of 
three independent replicates are plotted (n=3). The percentage of cells in all cell cycle phases is 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.3(d): Cell cycle distribution of HepG2 using flow cytometry after staining with 
propidium iodide (PI) before and after CEB4 treatment for 12 hours. I: Sub-G1; II: G0/G1; III: S; 
IV: G2/M. All experiments are a representative of a 10000 cell population and mean values of 
three independent replicates are plotted (n=3). The percentage of cells in all cell cycle phases is 
indicated. 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.3(e): Cell cycle distribution of MCF7 using flow cytometry after staining with 
propidium iodide (PI) before and after CEB4 treatment for 12 hours. I: Sub-G1; II: G0/G1; III: S; 
IV: G2/M. All experiments are a representative of a 10000 cell population and mean values of 
three independent replicates are plotted (n=3). The percentage of cells in all cell cycle phases is 
indicated. 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.3(f): Cell cycle distribution of HSC2 using flow cytometry after staining with 
propidium iodide (PI) before and after CEB4 treatment for 12 hours. I: Sub-G1; II: G0/G1; III: S; 
IV: G2/M. All experiments are a representative of a 10000 cell population and mean values of 
three independent replicates are plotted (n=3). The percentage of cells in all cell cycle phases is 
indicated. 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
 
 
In analysing the percentage of cells in all the cell cycle phases; sub-G1, G0/G1, S 
and G2/M, the difference between the treated and untreated cell lines was used in 
predicting the cell cycle arrest induced by CEB4 on the five tumour cell lines. 
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Percentage population of HSC4COX2- cells at sub-G1 before treatment was 1.97% 
and increased to 18.14%, and at G0/G1 the population cell cycle decreased from 64.08% 
to 32.85% after treatment. 
 
Percentage population of CaSki cells at sub-G1 before treatment was 2.07% and 
increased to 16.92%, and at G0/G1 the population cell cycle decreases from 55.79% to 
40.99% after treatment. 
 
 Percentage population of HepG2 cells at sub-G1 before treatment was 2.77% 
and increased to 14.49%, and at G0/G1 the population cell cycle decreased from 56.90% 
to 49.82% after treatment. 
 
 In the analyses on the HSC4COX2-, CaSki and HepG2 cells the reduction of G0/G1 
phase suggested that CEB4 inhibits cell cycle progression effects at the G0/G1 phase.  
 
In MCF7 cells, even though there was a decrease in the G0/G1 phase, but only a 
slight increase in the sub-G1 phase was observed with an increase from 0.29% - 2.92%. 
 
 In HSC2 cells even though there was a decrease in the G0/G1 phase, there was 
no change in the sub-G1 phase. 
 
Therefore the increase in the sub-G1 peak in all the cancer cell lines; HSC4COX2-, 
CaSki, HepG2 and MCF-7 cells except HSC2 suggested ongoing apoptosis which was 
not observed in the NHBE normal cells. 
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3.4 Annexin V assay by flow cytometry analysis 
 
 The Annexin V assay provides a simple and effective method to detect apoptosis 
at a very early stage. This assay takes advantage of the fact that phosphatidylserine (PS) 
is translocated from the inner (cytoplasmic) leaflet of the plasma membrane to the outer 
(cell surface) leaflet soon after the induction of apoptosis, and that the annexin V 
protein has a strong, specific affinity for PS. CEB4 treated cancer cells and NHBE cells 
at their respective IC50 values for 12 hours incubation was examined by flow cytometry.  
 
 As shown in figures 3.4 b-f, treatment of the tumour cell lines, at their IC50 
concentrations of CEB4 at 12 hours induced apoptotic cell death in all cell lines. There 
was no changes in NHBE cells (figure 3.4 a). After treatment of all five human tumour 
cell lines with CEB 4 for 12 hours, there was a shift in the viable cells population to 
early and late stage of apoptosis (II and III) followed by secondary necrosis (IV). 
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Figure 3.4 (a): Detection of apoptosis using annexin V-FITC and PI dual staining on NHBE. 
Untreated cells (left panel) before and treated cells (right panel) after CEB4 treatment for 12 
hours. Quadrants were designed as follows – I: non-stained cells indicating live cells; II: 
annexin V stained cells indicating early apoptosis; III: annexin V and PI stained cells indicating 
late apoptosis; and IV: PI stained cells indicating 2’-necrosis. All dot plots are a representation 
of an equal cell population (n=10,000). 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
 
 
 
 
 
 
 
 
 
 
Annexin V-FITC Annexin V-FITC 
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Figure 3.4 (b): Detection of apoptosis using annexin V-FITC and PI dual staining on HSC4COX2 . 
Untreated cells (left panel) before and treated cells (right panel) after CEB4 treatment for 12 
hours. Quadrants were designed as follows – I: non-stained cells indicating live cells; II: 
annexin V stained cells indicating early apoptosis; III: annexin V and PI stained cells indicating 
late apoptosis; and IV: PI stained cells indicating 2’-necrosis. All dot plots are a representation 
of an equal cell population (n=10,000). 
 
 
 
 
 
 
 
 
 
 
     
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.4 (c): Detection of apoptosis using annexin V-FITC and PI dual staining on HSC2. 
Untreated cells (left panel) before and treated cells (right panel) after CEB4 treatment for 12 
hours. Quadrants were designed as follows – I: non-stained cells indicating live cells; II: 
annexin V stained cells indicating early apoptosis; III: annexin V and PI stained cells indicating 
late apoptosis; and IV: PI stained cells indicating 2’-necrosis. All dot plots are a representation 
of an equal cell population (n=10,000). 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.4 (d): Detection of apoptosis using annexin V-FITC and PI dual staining on CaSki. 
Untreated cells (left panel) before and treated cells (right panel) after CEB4 treatment for 12 
hours. Quadrants were designed as follows – I: non-stained cells indicating live cells; II: 
annexin V stained cells indicating early apoptosis; III: annexin V and PI stained cells indicating 
late apoptosis; and IV: PI stained cells indicating 2’-necrosis. All dot plots are a representation 
of an equal cell population (n=10,000). 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.4 (e): Detection of apoptosis using annexin V-FITC and PI dual staining on HepG2. 
Untreated cells (left panel) before and treated cells (right panel) after CEB4 treatment for 12 
hours. Quadrants were designed as follows – I: non-stained cells indicating live cells; II: 
annexin V stained cells indicating early apoptosis; III: annexin V and PI stained cells indicating 
late apoptosis; and IV: PI stained cells indicating 2’-necrosis. All dot plots are a representation 
of an equal cell population (n=10,000). 
 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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Figure 3.4 (f): Detection of apoptosis using annexin V-FITC and PI dual staining on MCF7. 
Untreated cells (left panel) before and treated cells (right panel) after CEB4 treatment for 12 
hours. Quadrants were designed as follows – I: non-stained cells indicating live cells; II: 
annexin V stained cells indicating early apoptosis; III: annexin V and PI stained cells indicating 
late apoptosis; and IV: PI stained cells indicating 2’-necrosis. All dot plots are a representation 
of an equal cell population (n=10,000). 
 
 
 
 
 
 
 
 
 
 
Bar graph representing mean values from independent triplicate experiments. 
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 In analysing the shift in the viable cells populations (quadrant 1) to early 
(quadrant 2) and late stage of apoptosis (quadrant III) followed by secondary necrosis 
(quadrant IV), the highest percentage of early and late apoptotic cells were observed in 
HSC4COX2- cells with 63.32% followed by HSC2 with 55.46%. The three other cancer 
cell lines; CaSki, HepG2 and MCF7 showed lower levels of cell death with <50.00% of 
the cancer cell population being apoptotic. 
 
 
3.5 PARP analysis by Western blots   
 
 To further confirm apoptosis in the five human tumour cell lines, we studied the 
involvement of caspases in CEB4 induced apoptosis by investigating the expression and 
degradation of a nuclear protein, poly (ADP-ribose) polymerase (PARP). Proteolytic 
cleavage of PARP from a 116 kDa polypeptide to an 85 kDa large fragment is a typical 
marker for the onset of apoptosis. In figure 3.5 degradation of PARP was observed in a 
time dependent manner in all five of the CEB4 treated human tumour cell lines. These 
results support that CEB4 induces caspase activation and apoptosis in all five human 
tumour cell lines. 
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Figure 3.5: Induction of PARP degradation by CEB4 on HSC4COX2-, HSC2, CaSki, HepG2 and 
MCF7.Cancer cell lines were cultured in media and incubated with CEB4 at different 
incubation time. Equal amounts of cellular proteins were subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis, and PARP degradation from its native form (116kDa) to the 
cleaved form (89kDa) was detected by Western blot analysis. 
 
 
 The PARP cleavage is prominent in the two oral cancer cell lines, HSC4COX2- 
and HSC2 compare to in the other three cell lines CaSki, HepG2 and MCF7. Therefore 
the Western analysis of PARP cleavage confirms that CEB4 induces apoptosis in these 
cancer cells. 
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3.6 DNA fragmentation assay 
 
 
 This assay was performed to detect DNA cleavage in cancer cell lines to confirm 
results of flow cytometry and PARP analysis on HSC4COX2- and HSC2 cells. The 
apoptotic program is manifested in a diverse manner, and besides PARP cleavage, DNA 
undergoes cleavage from a high to low molecular weight DNA that run rapidly upon gel 
electrophoresis, forming a “DNA ladder”. 
 
 
Figure 3.6: Confirmation of apoptosis mediated cell death through observation of DNA 
laddering using DNA fragmentation assay on HSC4COX2- and HSC2. M: 100bp DNA size 
marker.  
 
 
 As seen in the gel figure 3.6, DNA from untreated HSC4COX2- cells (0 hour) 
presented no fragmentation. The untreated DNA (0 hour) was the negative control in 
this study. A slight DNA degradation was observed due to possible errors occurring 
during the cell harvesting and DNA extraction procedures. DNA from 12 and 24 hours 
of CEB4 treated HSC4COX2- cells showed DNA laddering on 0.1% agarose gel.  
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DNA from untreated HSC2 cells (0 hour) presented no fragmentation. DNA from 12 
and 24 hours of CEB4 treated HSC2 cells also showed DNA laddering on 0.1% agarose 
gel. 
Therefore, the compound CEB4 was confirmed to induce apoptotic mediated 
cell death as observed through the activation endonucleases-mediated nucleosome 
excision leading to the observation of DNA laddering of about 180-200 base pairs. 
Figure 3.6 (a-b) demonstrated partial and complete fragmentation of HSC4COX2- and 
HSC2 genomic DNA after 12 and 24 hours of CEB4 treatment respectively, which 
represent one of the major hallmark of apoptosis. 
 
3.7 Sandwich ELISA assay 
 
As CEB4 was shown to induce apoptosis in flow cytometry, Western analysis  
of PARP cleavage and DNA fragmentation, therefore the next pertinent question would 
be – how does it mediate its apoptotic effects? 
 
In the development of cancer, the tumour suppressor gene, p53 which controls 
apoptosis is frequently mutated and as a result the cancer cells would be protected from 
undergoing apoptosis. 
 
As activation (phosphorylation) of p53 leads to apoptosis, restoration of its 
function is an attractive therapeutic strategy to suppress tumour cell growth. To 
determine whether p53 plays an important role in the induction of apoptosis in the 
CEB4 mediated anti-proliferative effect on the five tumour cells, the level of this 
protein was assayed by Sandwich ELISA technique.  
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Results from the ELISA assay shows that treatment of tumour cells with CEB4 
stimulates phosphorylation of p53 at Ser15, as detected by PathScan® Phospho-p53 
(Ser15) Sandwich ELISA kit, without affecting the level of total p53 protein, as 
detected by PathScan® Total p53 Sandwich ELISA kit.  
 
Figure 3.7: Relative percentage of phosphorylated p53 (Ser15) in HSC4COX2-, HSC2, CaSki, 
HepG2 and MCF7 by using PathScan® Phospho-p53 (Ser15) Sandwich ELISA kit. Each value 
is the mean ±SD of three determinants. 
 
 
As observed in the graph figure 3.5, a 3.3 fold increase which is 39.2% of 
phosphorylated p53 was observed in 6 hours CEB4 treated HSC4COX2- cells and a 6.7 
fold increase which is 84.14 % was observed in 12 hours compared to the untreated 
HSC4COX2- cells. 
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A 3.0 fold increase, which is 32.5% of phosphorylated p53, was observed in 6 
hours CEB4 treated HSC2 cells and a 5.4 of fold increase, which is 58.5%, were 
observed in 12 hours compared to the untreated HSC2 cells. 
 
With the CaSki cells the level of phosphorylated p53 was not high in 
comparison to the two oral tumour cells where only a 2.9 fold increase, which is 28.1% 
of phosphorylated p53, was observed in 6 hours CEB4 treated CaSki cells and a 4.1 fold 
increase, which is 39.6%, was observed in 12 hours compared to the untreated CaSki 
cells. In HepG2 and MCF7 cells, the increment of phosphorylated p53 was less than 
35% compared to untreated HepG2 and MCF7 cells. 
 
In this ELISA analysis, the highest increment of phosphorylated p53 is in 
HSC4COX2- cells, followed by HSC2, CaSki, HepG2 and MCF7 which is in accordance 
with the apoptotic analysis carried out in this study. 
 
 
3.8 Expression of p53 and other p53 signalling related apoptotic proteins by       
      Western blot analysis 
 
 
 
The results of the p53 ELISA analysis suggest that CEB4 anti-cancer regulation 
may be mediated by this important tumour suppressor gene. The aims of the Western 
analysis on CEB4 treated HSC4COX2- cells were to analyze expression of p53 related 
apoptotic proteins and to understand their regulation modulated by this compound. 
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The expression of p53 and other p53 signalling related apoptotic proteins such 
as total p53, phosphorylated p53, Mdm2, Bcl-2, Bax, Caspase 3 and 9 were labeled with 
respective monoclonal antibodies and analyzed by western blots. 
 
 
 
Figure 3.8: Modulation of p53 and p53 signalling related apoptotic protein expression by CEB4 
in HSC4COX2-.  
 
 
 
p53 and its apoptotic related proteins levels were measured by semi- quantitative 
Western blot analysis after normalizing with β-actin. 
 
Results observed in Figure 3.8 showed that upon CEB4 treatment, expression of 
p53 increased from 6 hours to 12 hours, expression of the inhibitor of p53, Mdm2, 
decreased after 6 hours and further decline after 12 hours. The level of total p53 was 
high in HSC4COX2- cells and remained almost unaltered after CEB4 treatment.  
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On the other hand, the level of the pro-apoptotic Bax increased significantly 
after 6 hours and attained a peak at 12 hours after CEB4 treatment while the expression 
level of anti-apoptotic Bcl-2 decreased simultaneously with the change in expression of 
Bax. Interestingly, the increase in expression of phosphorylated p53 was observed 
together with the increase of Bax expression in HSC4COX2- cells as a result of CEB4 
treatment.  
 
 In investigating further downstream caspases, the expression of the activator 
caspase 9 and the executioner caspase 3 decreased as they were cleaved but, only one of 
the cleaved fragments was observed in the Western blot analysis. 
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CHAPTER 4.0: DISCUSSION 
 
 
 Plants have a long history of use in the treatment of cancer. Plant-derived 
compounds have been an important source of several clinically useful anti-cancer 
agents. These include vinblastine, vincristine, the camptothecin derivatives, topotecan 
and irinotecan, etoposide, derived from epipodophyllotoxin, and paclitaxel (taxol®) 
(Cragg et al., 2005). Malaysia has vast potential in production of such drugs due to its 
mostly untapped biodiversity and its traditional use of plants in treatment of various 
diseases.  
 
 Currently, the desired cytotoxic effect of most chemotherapeutic drugs is to 
induce apoptosis in cancer cells. Apoptotic mediated cell death is favored because it 
does not involve the sudden release of pro-inflammatory mediators which would lead to 
induction of inflammation, as compared to necrosis with its sudden release of pro-
inflammatory mediators and induction of inflammation (Vakkila and Lotze et al., 2004). 
There is also much accumulated knowledge about apoptosis and the mechanisms that 
these drugs induce the apoptotic pathway in various cancer types. 
 
 In this study, erythrocarpine E (CEB4) a new cytotoxic limonoid was isolated 
from the dichloromethane extract of the bark from Chisocheton erythrocarpus Hiern 
which was collected from Hutan Simpan Terenas, Kedah, and Malaysia. This plant is 
commonly known as Rongga in Malaysia. It is a big tree that can grow up to 80 feet tall 
with the branchlets velvety tomentose. Its leaves are 12 to 15 inches long with 4-6 pairs 
of coriaceous elliptic-oblong or broad ovate leaflets. The flowers are about 0.35 inches 
long with its petals elliptic silky outside and stamen-tube shorter silky below. The seeds 
are ex-arillate to about 1 inch and are orange red in colour.  
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 CEB4 was repeatedly purified over silica gel column chromatography using 
solvent mixture (hexane: ethyl acetate) with increasing polarity identified as 
erythrocarpine E or CEB4 through spectroscopic methods; UV, IR, NMR, and MS. 
 
 MTT assays were performed to assess cytotoxicity of CEB4 on the various 
cancer cell lines; oral (HSC4COX2- and HSC2), cervical (CaSki), liver (HepG2), breast 
(MCF7) and normal human bronchial epithelial (NHBE) cell line and the inhibition 
concentrations (IC50) of CEB4 were determined on these cancer cell lines. CEB4 
treatment was performed in time and dosage dependent manner on the five cancer cell 
lines. The NHBE cell line acts as positive control throughout this study. CEB4 had 
cytotoxic effects on all five human cancer cells lines with the percentage of total viable 
cells observed in time and dose dependant manner. IC50 values were assessed at 12 
hours because viability of all cancer cells reduced and reaches only 50% at 12 hours. 
The IC50 values were summarized in table 3.1 and all further experiments were 
conducted using these IC50 values as shown in table 3.1 to treat all the cancer cell lines 
respectively.  
 
 Minimal cytotoxic effect of CEB4 was observed on NHBE cells where 
approximately 80.0% cell viability after 24 hours of incubation at 40.0µM. This 
reinforces that the cytotoxic effect of CEB4 was only on cancer cell lines. Viability of 
cells treated with DMSO without CEB4 insignificantly affected (<1.0 %) (data not 
shown), indicating that cytotoxicity was induced by CEB4 and not the solvent used to 
dissolve the compound. Both time and dose dependant assays supported the need to 
further investigate the apoptotic effects of CEB4 and its potential as an anti-cancer drug 
for the treatment of cancer. 
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LIVE/DEAD® Viability/Cytotoxicity Assay Kit was used to further confirm the 
cytotoxic effect of CEB4 on the normal and five cancer cell lines. Live cells are 
distinguished by the presence of ubiquitous intracellular esterase activity, determined by 
the enzymatic conversion of the virtually non-fluorescent cell-permeant calcein AM to 
the intensely fluorescent calcein. The polyanionic dye calcein is well retained within 
live cells, producing an intense uniform green fluorescence in live cells (ex/em ~495 
nm/~515 nm). EthD-1 enters cells with damaged membranes and undergoes a 40-fold 
enhancement of fluorescence upon binding to nucleic acids, thereby producing a bright 
red fluorescence in dead cells (ex/em ~495 nm/~635 nm). EthD-1 is excluded by the 
intact plasma membrane of live cells. Therefore the determination of cell viability 
depends on these physical and biochemical properties of cells. 
 
 These cytotoxicity results provided a visual confirmation of the MTT assay 
results and cell death were seen in all cell lines. The control experiment with the normal 
cells, NHBE, showed no killing after treatment with CEB4.  
 
 Evidence from these two results showed that indeed this drug induces cytotoxic 
effects on all the five cell lines and the effect was cell type dependent, in which some 
cell lines were more sensitive to the compound as compared to others. Both time and 
dose dependent assays supported the need to further investigate the apoptotic effects of 
CEB4 and its potential as an anti-tumour drug for the treatment of cancer. Its minimal 
cytotoxic effect on the normal NHBE cells was also desirable as it implies its safety in 
being a potential chemotherapeutic agent. 
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 Apoptosis is a major mode and desirable cell death in response to cytotoxic drug 
treatment. Induction of apoptosis and inhibition of tumor cell proliferation have been 
used as markers for evaluation of phytochemical anti-cancer activities. Many 
chemotherapy agents causes disturbance in the cell cycle progression or induce 
apoptosis in cancer cells. The cell cycle is simply the program for cell growth and cell 
proliferation (Tolis et al., 1999). Thus, cell cycle modulation could serve as an effective 
method in investigating the regulation of cell proliferation. 
 
 CEB4 treatment on the five cancer cells indicates suppression of viability of 
cancer cell could be partially explained by the bioactive effects of this compound on 
cell-cycle control and apoptosis induction. All the five cancer cell lines; HSC4COX2-, 
HSC2, CaSki, HepG2 and MCF7 were treated with CEB4 at their respective IC50 values 
at 12 hours incubation but only CEB4 treated HSC4COX2-, CaSki, HepG2 and MCF7 
showed cell cycle progression as demonstrated in the flow cytometry analysis. There 
were no changes observed in HSC2 cells. CEB4 also did not show any cytotoxic effect 
on NHBE cell line. 
 
 In analysing the percentage of cells in all the cell cycle phases; sub-G1, G0/G1, S 
and G2/M, the difference between the treated and untreated cell lines was used in 
predicting the cell cycle arrest induced by CEB4 on the five tumour cell lines. In the 
present study, treatment with the purified natural compound CEB4 on HSC4COX2-, 
CaSki and HepG2 cells results in reduction of G0/G1 phase, which suggest that CEB4 
inhibits cell cycle progression at the G0/G1 phase. Detection of hypodiploid (apoptotic) 
sub-G1 peak population of cells in the cancer cell lines; HSC4COX2-, CaSki, HepG2 and 
MCF-7 cells except HSC2 confirms CEB4 role as an inducer of apoptosis.  
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 As it stands results from cell cycle analysis is insufficient to conclude that CEB4 
has any effect on cell cycle progression. It is possible that the 12 hours time point is 
insufficient for the cell cycle progression to complete in order to assess effect of CEB4 
on cell cycle. This could be reason there were no changes observed in the HSC2 cells.  
 
 Three types of assays were conducted to confirm apoptotic effect of CEB4 in the 
five human cancer cells; annexin V, PARP cleavage and DNA fragmentation assays. 
Extensive studies have been conducted to gain knowledge about cell proliferation in 
comparison to the occurrence, duration and frequency of apoptosis in tumours. The 
changes from early stages to the end-stage apoptotic bodies that undergo rapid 
phagocyte takes only a few hours without the unwanted inflammatory reaction. Changes 
on the surface of apoptotic cells, such as the expression of thrombospondin binding 
sites, loss of sialic acid residues and exposure of phosphatidylserine (PS) have been 
difficult to recognize. PS is a negatively charged phospholipid that is predominantly 
present in membrane leaflets facing the cytosol. Surface exposure of PS has been 
reported for activated platelets and senescent erythrocytes and recently it was shown in 
cells undergoing apoptosis. 
 
 Annexin V has the biological property of binding to phospholipids in a Ca2+ 
dependent way. Annexin V binds preferentially to phospholipid species such as PS. 
During apoptosis PS is translocated to the external surface of the cell membrane. This 
occurs in the early phases of apoptotic cell death during which the cell membrane itself 
remains intact. On the other hand, necrosis is accompanied by loss of cell membrane 
integrity and leakage of cellular constituents into the environment. Therefore the 
measurement of annexin V binding, executed simultaneously with a dye exclusion test, 
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would provide a perfect assay to detect apoptotic cells and to discriminate between 
apoptosis and necrosis (Vermes et al., 1995). 
 
 It was seen in earlier studies by Shounan et al., 1998, that during apoptosis, the 
plasma membrane undergoes changes that allow phagocytes to recognize and engulf 
these cells before they rupture. The apoptotic stimulus externalization of PS occurs 
earlier than the nuclear changes. 
 
 Thus, the FITC conjugated annexin V binding assay of PS detects early phases 
of apoptosis before the loss of cell membrane integrity. This allows the measurement 
and scoring of individual apoptotic cells by fluorescence activated cell sorting FACS 
and fluorescence microscopy and makes an ideal test for the measurement of cell-
mediated cytotoxicity.  
 
 Further, when annexin V apoptosis assay is combined by double staining with 
propidium iodide (PI) staining, it can analyze morphology changes, detection of 
phospholipid asymmetry and plasma membrane integrity. When membrane integrity is 
lost, as seen in the later stage of cell death resulting from either the apoptotic or the 
necrotic processes, the PI staining becomes positive. Therefore when results are only 
annexin V-positive, it only contains apoptotic cells whereas cells stained with both 
Annexin V-FITC and PI is referred to as late apoptotic (Nigam et al., 2008). 
 
 The effectiveness of CEB4 on the five human cancer cell lines and normal 
human bronchial epithelial cell line (NHBE) for apoptosis induction was examined by 
flow cytometry determination of annexin V-positive cells at 12 hours after treatment 
with this drug. An increase in cellular staining with FITC conjugated annexin V served 
as an early marker for apoptosis. The cells were simultaneously stained with PI to  
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investigate loss of cell membrane integrity. The double staining procedure distinguishes 
early stage apoptotic cells (annexin V-positive) from late stage apoptotic cells (annexin 
V-positive, PI-positive). 
 
Upon exposure of all five human cancer cell lines to CEB4 treatment for 12 
hours, the population of cells indicated a shift from viable cells to early stage and late 
stage apoptosis followed by secondary necrosis. In analysing the flow cytometry results, 
the annexin V-positive apoptotic cells after 12 hours of treatment with CEB4, the early 
apoptotic cells were higher in the two oral cell lines, HSC4COX2- and HSC2 in contrast 
to the liver cells (HepG2), cervical cells (CaSki), and breast cells (MCF7) cells. In this 
preliminary study of flow cytometry, it certainly suggests CEB4 to be most effective on 
the two oral cell lines HSC4COX2- and HSC2.  
 
In both HSC4COX2- and HSC2, nearly equal amount of early apoptotic cells, 
approximately 40.0% were observed upon treatment with CEB4, with a slightly higher 
percentage, 21.44% of late apoptotic cells for HSC4COX2- compared to the 11.64% for 
HSC2. 
 
In contrast, CaSki and HepG2 showed lower apoptotic effects after treatment 
with CEB4 with amounts less than 30% in the second quadrant, with an even lesser 
amount (approximately 16%) in MCF7 cells. 
 
The flow cytometry analysis confirmed that cytotoxicity in the MTT assay was 
apoptotic, and that CEB4 induced apoptosis in HSC4COX2-, HSC2, CaSki, HepG2 and 
MCF7 cells. 
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 Apoptosis is normally characterized by morphological and biochemical changes. 
Morphological changes include membrane blebbing, cellular shrinkage and chromatin 
condensation. Biochemical changes involve an activation of cascades of proteases such 
as caspases and endonucleases, cleavage of poly-AD ribose polymerase (PARP) and 
fragmentation of genomic DNA (Jessie et al., 1999).  
 
PARP is a DNA binding protein that recognizes DNA strand breaks and is 
implicated in DNA repair and in the apoptotic response of cells. PARP functions by 
adding poly (ADP-ribose), in an ATP and NAD dependent manner, to various proteins 
in response to DNA damage and has been shown to directly interact with DNA 
polymerase.  
 
Caspase 3 is known to be involved in a cascade of cleavage events that disable 
key homeostatic and repair enzymes including PARP, which serves as a biological 
substrate for caspases. Caspases are activated during apoptosis and in turn cleaves 
PARP and correlates well with chromatin condensation and precedes the ability to 
detect actual DNA fragmentation. Proteolytic cleavage of PARP from a 116 kDa 
polypeptide to an 85 kDa fragment is a typical marker for the onset of apoptosis (Pillai 
et al., 2004). 
 
There are many studies carried out to identify the events that occur during early 
stages of apoptosis and to establish a reliable hallmark of apoptosis. One of it by 
Bursztajn et al., 2000, showed that an increase in PARP protein and the cleavage of 
PARP are early signs of apoptosis that occur before any morphological and other 
measurable parameters of apoptosis can be detected. This increase in caspase 3 activity  
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precedes PARP cleavage. Changes in PARP protein and the appearance of PARP 
cleavage product was observed 1 hour after exposure to staurosporine. 
 
They showed for the first time that caspase 3 activity and PARP cleavage is 
readily detectable at a much earlier time point than any other morphological and 
biochemical indices of apoptosis or cytotoxicity tested. Therefore, caspase 3 activity 
and PARP cleavage can serve as an early hallmark of apoptosis. 
 
 To further confirm apoptosis in the five human cancer cell lines, we studied the 
CEB4 treated cancer cells by investigating the expression and degradation of this 
nuclear protein, PARP from a 116 kDa polypeptide to an 85 kDa fragment. In this 
study, degradation of PARP was observed in a time dependent manner in the cancer cell 
lines treated with CEB4. The results support that CEB4 induces apoptosis in all five of 
the human cancer cell lines and maybe through caspase activation. However the 
intensity of band in Western blotting of PARP protein was high in the two oral cell 
lines, HSC4COX2- and HSC2. The protein band was seen at a lower intensity in the other 
three cell lines CaSki, HepG2 and MCF7. Therefore the Western analysis of PARP 
confirms the flow cytometric analysis.  
 
 The apoptotic program is manifested in a diverse manner, and besides PARP 
cleavage, DNA undergoes cleavage from a high to low molecular weight DNA that run 
rapidly upon gel electrophoresis, forming a “DNA ladder”. Cleavage of PARP prevents 
its enzymatic function in DNA repairing. This is followed by activation of a 
calcium/magnesium-dependent endonucleases, and results in inter-nucleosomal DNA 
fragmentation.  
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Cleavage of DNA fragmentation factor is also associated with inter-nucleosomal DNA 
fragmentation. During the inter-nucleosomal DNA fragmentation, nuclear DNA was 
sequentially degraded to about 300 kb, 50 kb, and then about 200 bp fragments (Nigam 
et al., 2008).  
 
DNA fragmentation is a late event in apoptosis that is frequently used to confirm 
apoptotic death, where the fragmented DNA is released into the cytoplasm as a DNA-
histone complex (Jessie et al., 1999). 
 
 The cancer cell lines with the prominent results for flow cytometry and PARP 
analyses, HSC4COX2- and HSC2, were further investigated using the DNA fragmentation 
assay. As seen in the gel, DNA from untreated HSC4COX2- and HSC2 cells (0 hour) 
presented no fragmentation. The untreated DNA was the negative control in this study.  
 
            A slight DNA degradation was observed which may be due to degradation 
during the cell harvesting and DNA extraction procedures. Alternatively, the smearing 
in the agarose gel picture was possibly caused by random DNA fragmentation, which 
occurs in necrosis. Theoretically, DNA fragmentation process in late stage of apoptosis 
would be very similar to random DNA fragmentation in necrosis. This random and non-
specific DNA fragmentation, together with asynchrony of apoptotic entry was proposed 
as a possible reason for the occurring of mixed smearing and laddering of DNA 
fragments together in gels (Collins et al., 1997). This may explain the CEB4-induced 
early apoptosis as clear laddering and smearing for late apoptosis or necrosis.  
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 Therefore CEB4 was confirmed to induce apoptotic mediated cell death. The 
occurring of DNA ladder for treated HSC4COX2- and HSC2 cell can be explained by the 
DNA degradation in an inter-nucleosomal pattern. Indeed, the DNA cleavage during 
apoptosis occurred at sites between nucleosome, which are protein-containing structures 
that occur in chromatin at approximately 200 bp intervals (Collins et al., 1997). 
 
 HSC4COX2- and HSC2 demonstrated partial and complete fragmentation of 
genomic DNA after 12 and 24 hours of CEB4 treatment respectively, which represent 
one of the major hallmark of apoptosis. 
 
 Apoptosis is a highly synchronized cell death program which requires the 
communication of complex pathways including extrinsic, intrinsic, p53, and nuclear 
factor kappa B pathways, and also by Bcl-2 family members. The tumour suppressor 
p53 is a protein that has a critical role in preventing cancer where common target for 
genetic alterations in human cancer, with point mutations or deletions in the p53 gene 
present in more than 50% of cases. The status of the p53 gene is considered to be an 
important determinant of tumour sensitivity to anticancer therapies. Phosphorylated p53 
induces either cell cycle arrest or programmed cell death through transcriptional 
activation of inhibitor of cell cycle or pro-apoptotic proteins (Viktorsson et al., 2005). 
  
As CEB4 was shown to induce apoptosis in flow cytometry, Western analysis of 
PARP cleavage and DNA fragmentation, Sandwich ELISA technique was used to 
determine whether tumour suppressor gene p53 played an important role in the 
induction of apoptosis which is commonly mutated in cancer in the CEB4 treated five 
cancer cell lines  
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 Results from the ELISA assay shows that treatment of tumour cells with CEB4 
stimulates phosphorylation of p53 at Ser15, detected by PathScan® Phospho-p53 
(Ser15) Sandwich ELISA kit without affecting the level of total p53 protein, detected by 
PathScan® Total p53 Sandwich ELISA kit.  
 
Sandwich ELISA technique was performed on the five tumour cell lines, 
HSC4COX2-, HSC2, CaSki, HepG2, and MCF7 treated with CEB4 at post 12 hours 
treatment. In this ELISA analysis, the highest increment of phosphorylated p53 is in 
HSC4COX2- cells, followed by HSC2, CaSki, HepG2 and MCF7, which are in 
accordance with the apoptotic analysis carried out in this study.  
 
It would be interesting to investigate if CEB4 induces phosphorylation sites at 
other serine residue than at only Ser15, such as serine residues 20, 37, or 40, by using 
sandwich ELISA or Western blotting techniques.  
 
In addition, CEB4 might also induce phosphorylation event on other molecules 
that could trigger cell to undergo apoptosis. Hence it is possible that modification on 
other proteins such as Mdm2 may contribute to the stability of p53 since there is 
evidence that the phosphorylation mechanism itself maybe insufficient to activate p53 
protein (Maya et al., 2001).  
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One possible mechanism for CEB4 to phosphorylate Mdm2 is via ATM kinase. 
Rami et al., 1999, showed that ATM phosphorylates the carboxyl terminal end of 
Mdm2 by blocking the Mdm2 from targeting p53 for degradation. Therefore CEB4 
might play a role in inducing phosphorylation of Mdm2 by ATM and eventually 
increase stability of p53 proteins to trigger apoptosis on human cancer cell lines. In 
verify this assumption; further investigations needs to be carried out to examine 
phosphorylation of Mdm2 by ATM-dependent manner on CEB4 treated human cancer 
cell lines. 
 
In addition, CEB4 might probably induce the ubiquitination of Mdm2 in treated 
human cancer cell lines. Degradation of Mdm2 will promote the activation of tumour 
suppressor protein, p53, to trigger the cell to undergo apoptosis by transcriptionally 
regulating pro-apoptotic genes. A natural product, parthenolide, an anti-inflammatory 
agent, was shown to induce ubiquitination of Mdm2 in treated cells and subsequent 
activation of p53 (Gopal et al., 2009). 
 
Besides phosphorylation, other post-translational modification such as 
acetylation could promote p53 stability. Li et al., (2002) showed that acetylation of p53 
at C-terminal domain had abrogated the Mdm2 mediated ubiquitylation and degradation 
of p53. In addition acetylation of p53 proteins by acetylases p300 could enhance the 
sequence-specific DNA binding activity (Liu et al., 2000). Accordingly this might then 
suggest that acetylation may be a physiologic response to activate p53 as a tumor 
suppressor protein and to activate anti-apoptotic proteins. In contrast, suppression of 
p53 acetylation would render its transactivation properties. 
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Thus different modification such as acetylation of p53 proteins and consequently 
leading to p53 dependent apoptosis could be a possible explanation that no elevation in 
the level of phosphorylated p53 (Ser15) was observed in HepG2 and MCF7 treated 
tumour cell lines as in both cell lines cell death was seen. In order to verify this 
possibility, further investigation can be done by using acetyltransferase assay to 
evaluate the HepG2, MCF7, CaSki and HSC2 cells after treatment with CEB4. 
 
The mechanism and order of events of anti-proliferation, induction of apoptosis 
and p53 expression by CEB4 towards human tumour cells deserves further 
investigation. Therefore in this study, the mechanism of action of CEB4 on the 
apoptotic effects; the expression of total p53 in the cancer cell and phosphorylated p53 
at Ser 15 and several apoptotic related proteins (e.g. Mdm2), anti apoptotic protein (e.g. 
Bcl-2), pro-apoptotic protein (e.g. Bax), the activator caspase 9 and the executioner 
caspase 3 were quantified by Western blot analysis on oral squamous cell line, 
HSC4COX2- which showed highest cytotoxic and apoptotic effect upon treatment with 
CEB4. However the mechanism of apoptosis induction is still unknown. Signaling 
pathway of activating p53 protein is complex as until today, a complete pathway 
describing the triggering of p53 activation is still unknown. Therefore the exact 
mechanisms of how CEB4 modulating p53 activation remains to be elucidated.  
 
p53 and its apoptotic related proteins levels were measured by semi- quantitative 
Western blot analysis after normalizing with β-actin. Results shows that upon CEB4 
treatment, expression of p53 increases from 6 to 12hours, expression of the inhibitor of 
p53, Mdm2, decreases after 6 hours and further decline after 12 hours. It is an important 
point that CEB4 can reduce Mdm2 for it to be a possible anti-cancer agent. 
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 Mdm2 has been considered a major p53 regulator. Mdm2 is known to function 
as an oncoprotein and its mode of action is to antagonize p53 and thereby prevent 
entrance of a cell into cell cycle arrest or prevent entrance into the apoptotic suicide 
program with a final outcome that favours an increase in cell number. The Mdm2 
protein was shown to bind and inhibit p53. Mdm2 can inhibit p53 in two major ways, 
first, by interacting with p53 and block the basal transcription machinery and 
transcriptional co-activators such as p300.  
 
Second, through ubiquitin-mediated proteasomal degradation regulate the p53 
stability. Inhibiting Mdm2 activity in tumours that express wild-type p53 has been 
considered an attractive anticancer strategy for many years. Analysis of the Mdm2-p53 
interface by crystallography indicated that only 3 N-terminal amino acids in p53 are 
essential for Mdm2-p53 interactions (Toledo et al., 2007). Amplification of the Mdm2 
gene is now reported in more than 10% out of 8000 human cancers from various sites.  
 
This study shows activation of p53 signaling related apoptotic proteins and up-
regulation and down-regulation of p53 signaling proteins. β-actin and total p53 protein 
were used as internal control. Treated HSC4COX2- with CEB4 showed the 
phosphorylated p53 at Ser15 were up-regulated while the Mdm2 was down regulated, 
where the results show that CEB4 may induce apoptosis via p53 signaling pathway 
which is phosphorylated at Ser15. Direct experimental evidence for the actual 
phosphorylation of p53 by CEB4 at Ser15 is unknown. However, phosphorylation of 
p53 by CEB4 at Ser15 might lead to reduced interaction of p53 with its negative 
regulator, oncoprotein Mdm2.  
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On the other hand, the level of the pro-apoptotic Bax increases significantly after 
6 hours and attained a peak at 12 hours after CEB4 treatment, while the expression level 
of anti-apoptotic Bcl-2 decreases simultaneously with the change in expression of Bax. 
Interestingly, the increase in expression of p53 was observed together with the increase 
of Bax expression in HSC4COX2- cells as a result of CEB4 treatment. Since it is known 
that p53 can transactivate Bax expression, it is perhaps a possibility that the CEB4 
induces HSC4COX2- apoptosis via the p53-dependent pathway in which Bax is a 
downstream molecule.  
 
Bcl-2 family proteins are one of the regulators of apoptosis and they represent a 
critical checkpoint within most apoptotic pathways by acting upstream at irreversible 
damage in cells. At least 15 bcl-2 family members have been identified so far in 
mammalian cells. They function either as pro-apoptotic (Bax, Bak, and Bad) or anti-
apoptotic (Bcl-2, Bcl-XL) regulators. These proteins form heterodimers of anti- and pro-
apoptotic members thereby influencing one another’s function. The ratio of anti-
apoptotic and pro-apoptotic proteins determines how cells respond to apoptotic or 
survival signals. Over expression of Bcl-2 and Bcl-XL enhances cell survival by 
suppressing apoptosis and over expression of Bax accelerates cell death upon growth 
factor withdrawal (Hsu et al., 1997). 
 
Since apoptosis is a complex pathway that can be regulated by many factors, 
only two apoptotic genes were targeted in this study. Western analysis results show up-
regulation in Bax expression and down-regulation in Bcl-2 expression in the CEB4 
treated HSC4COX2-. It has been proposed that the balanced ratio between Bcl-2 and Bax 
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regulates the apoptotic pathway by dimerizing with each other or themselves 
(Matsumoto et al., 2004). 
 
An interesting explanation for the role of Bax in apoptosis induction has recently 
been offered in the context of PUMA. The PUMA gene is also directly induced by p53 
in response to DNA damage. In humans, PUMA encodes two BH3-domain-containing 
proteins, PUMA-a and PUMA-b (Yu et al., 2001). A vital balance between PUMA and 
p21 has been identified to determine the onset of arrest, or in response to exogenous p53 
expression and also hypoxia in human colorectal cancer cells. Growth arrest through 
activation of p21 is the normal response to p53 expression in these cells. If p21 is 
disrupted the cells die through apoptosis and if PUMA is disrupted, apoptosis is 
prevented. Therefore Bax is absolutely required for PUMA mediated apoptosis. PUMA 
expression promotes mitochondrial translocation and multimerization of Bax, end in 
apoptosis induction (Yu et al., 2003).  
 
Thus, although p53 can bind to the Bax promoter, the affinity is weak in contrast 
to p21 and PUMA binding (Kaeser and Iggo, 2002). Bax thus participates in the death 
response as an indirect target of p53 through PUMA (Yu et al., 2003). In response to 
DNA damage, p53 activates the intrinsic mitochondrial apoptotic pathway by inducing 
the expression of at least three Bcl-2 pro-apoptotic family members, shifting the balance 
towards pro-apoptotic effects (Oda et al., 2000). 
 
Therefore, the exact target of CEB4 on the apoptotic gene remains to be 
elucidated. Hence, further study on other bcl-2 family genes is needed to be carried out 
to figure out the activity and effect of CEB4 in targeting the apoptotic gene to modulate 
apoptosis.  
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The mechanism of action of CEB4 in apoptotic cells includes not only cellular 
and molecular biological features, such as cell shrinkage and DNA fragmentation, but 
also activation of p53 signaling molecules and several apoptotic related proteins were 
observed which leads to activation of caspase cascade, which is a well known molecular 
mechanism for the induction of apoptosis.  
 
One of the major signaling pathways involved in apoptotic cell death includes 
the intracellular caspases, a family of structurally related cysteine proteases. Caspase 
activity is responsible, either directly or indirectly, for the cleavage of cellular proteins, 
which are characteristically proteolyzed during apoptosis. In response to stress 
activation, Bax forms a homodimer and releases cytochrome c from the mitochondria 
(Skulachev et al., 1998), which results in the activator caspase 9 activation. For 
example, caspase 2, 3, 6, 7 and 9 can cleave poly (ADP ribose) polymerase (PARP).  
 
In obtaining further insight into the mechanism of CEB4 action, we studied the 
expression of activator caspase 9 and executioner caspase 3 – the two major players in 
apoptotic cell death. In the  investigation further downstream caspases, the expression 
of the activator caspase 9 and the executioner caspase 3 decreased as they are cleaved, 
results of this experiment suggest the possibility that the mechanism of CEB4 induced 
apoptosis in cancer cells involve the activation of both these caspases .  
 
However the smaller cleaved fragments were not detected in this analysis. The 
caspase 3 antibody detects endogenous levels of full length caspase 3 (35 kDa) and the 
large fragment of caspase 3 resulting from cleavage (17 kDa), while the caspase 9 
antibody detects endogenous levels of full length caspase 9 (47 kDa) and large  
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fragments of caspase 9 (37 kDa and 35 kDa). Caspases have been shown to be activated 
during apoptosis in many cell systems and play critical roles in both the initiation and 
the execution of apoptosis.  
 
  The activation of activator caspase 9 upon CEB4 treatment may activate other 
caspases leading to an expanding cascade of proteolytic activity within the cell and to 
activate executioner caspase 3. This results in the digestion of structural proteins in the 
cytoplasm, chromosomal DNA degradation and phagocytosis of the cell. Cell death is 
said to follow a classical apoptotic mode if execution of cell death is dependent on 
caspase activation. This perhaps is the cause of apoptosis to the tumour cells as seen in 
the apoptotic analysis. 
 
 According to Calviello et al., 2003, treatment of HL-60 cells with Tocopheryl 
quinine (TQ) resulted in activation of upstream caspase 9 and of the downstream 
caspase 3. The early activation of caspase 9 suggests that the TQ pro-apoptotic effect 
may be elicited mainly via the mitochondrial pathway. It is known that cytochrome c 
released from mitochondria into the cytosol binds to the apoptotic protease activating 
factor (Apaf) complex and triggers the activation of procaspase 9 to the active caspase 9. 
The close association of the release of cytochrome c from mitochondria with the 
concurrent increase in caspase 9 provides evidence that TQ induces apoptosis in HL-60 
cells through the mitochondrial pathway. TQ also induce apoptosis by the activation of  
the downstream caspase 3, which has been shown to play an important role in apoptosis. 
The study shows that caspase 3 activation was preceded by the activation of caspase 9, 
the apical caspase of the intrinsic mitochondrial pathway of apoptosis.  
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 Another study shows that paclitaxel, a Taxane derivative, triggers apoptosis not 
through caspase 10, but via caspase 9 activation by apoptosome. In their study they used 
different cellular models with deficiencies in key regulators of apoptosis to elucidate the 
mechanism of paclitaxel-induced cell death. 
 
 Caspase 3 activity has been described to be essential for drug-induced apoptosis. 
Recent results suggest that in addition to its downstream executor function, caspase-3 is 
also involved in the processing of upstream caspase 8 and 9. Blanc et al., 2000, have 
published data to suggest that caspase 3 is not only involved in executing the apoptosis 
but is also essential for the processing of upstream procaspase 9 in cisplatin-induced 
apoptosis. 
  
 According to Enari et al., 1998, caspase 3 seems to play a central role in 
chemotherapy-induced apoptosis. It is specifically required for DNA fragmentation 
leading to the typical apoptotic pattern of DNA laddering. In some cell lines, caspase 3 
plays a direct role in proteolytic cleavage of cellular proteins responsible for progression 
to apoptosis. Lu et al., 2009, has shown that caspase 3 is involved in apoptosis and the 
activation of caspase 3 is considered to be the final step in many apoptosis pathways.  
 
 The activation of caspase 3 induces PARP cleavage, chromosomal DNA break 
and finally the occurrence of apoptosis. These results show for the first time that 
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, isolated from the  
traditional Chinese herb Artemisia annua, is recommended as the first-line anti-malarial 
drug with low toxicity can inhibit proliferation and induce apoptosis via caspase 3 
dependent mitochondrial death pathway in ASTC-a-1 cells. 
 92 
 
 All these studies reinforce that association of activator caspase 9 and the 
executioner caspase 3 may lead to apoptosis. The CEB4 treated HSC4 COX2- shows 
activation of caspase 9 and 3 which are shown to be activated during apoptosis in many 
cell systems and play critical roles in both the initiation and the execution of apoptosis. 
So CEB4 may induce apoptosis via the mitochondrial pathway. Hence, further study on 
apoptosis via mitochondrial pathway is needed to be carried out to figure out the 
activity and effect of CEB4 in targeting the apoptotic gene to modulate apoptosis. 
 
 Western blot results demonstrated that CEB4 causes growth arrest and apoptosis 
in human oral cancer cell line, HSC4 COX2-, and the apoptotic ability of CEB4 appeared 
to be mediated by the regulation of p53, phosphorylated p53, Mdm2, Bcl-2, Bax, 
activator caspase 9 and the executioner caspase 3. 
  
 Therefore since CEB4 shows activation of p53 tumour suppressor protein, 
modification of CEB4’s structure to increase its cytotoxic ability can be carried out to 
improve activation of p53. It would be interesting to understand the exact mechanism 
on how CEB4 stimulate phosphorylation of p53 with an aim to enhance CEB4’s 
potential as an anticancer agent. 
 
 The apoptotic pathway is one of the most sophisticated pathways discovered in 
the cell to date. Its activity is tightly regulated and monitored by the cell. Recent 
advances and understanding of the apoptotic pathway have led to better and more 
innovative treatments against cancer and other diseases. However, the detailed 
mechanism of the apoptotic pathway is still waiting to be elucidated.  
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In summary, CEB4 was found to have cytotoxic and apoptotic effect on 
HSC4COX2-, HSC2, CaSki, HepG2 and MCF7. These results show that CEB4 may 
inhibit dose and time dependent cell proliferation and may induce apoptosis via p53 
signaling pathway. CEB4 up-regulates pro-apoptotic genes and at the same time down-
regulate the anti-apoptotic genes. It also activates activator caspase 9 and executioner 
caspase 3, which are downstream molecules to induce apoptosis. Furthermore, our data 
provides evidence of potential implications for the rational application of CEB4 as a 
novel potential anticancer drug against human cancer although much work is needed 
before CEB4 can be fully utilized in clinical treatments. 
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CHAPTER 5.0: CONCLUSION 
 
 
 The apoptotic pathway is one of the most sophisticated pathways discovered in 
the cell to date. Its activity is tightly regulated and monitored by the cell. Recent 
advances and understanding of the apoptotic pathway have led to better and more 
innovative treatments against cancer and other diseases. However, the detailed 
mechanism of the apoptotic pathway is still waiting to be elucidated.  
 
Natural compounds are being investigated extensively worldwide as potential 
anti-cancer agents. Most of the natural anti-cancer agents available today are derived 
from plants, animals, marine organisms or microorganisms. In this study, erythrocarpine 
E (CEB4), extracted from Chisocheton erythrocarpus Hiern is being investigated as a 
potential natural compound to induce apoptosis in cancer cell lines.  
 
CEB4 were treated on five cancer cell lines; oral (HSC4COX2- and HSC2), 
cervical (CaSki), liver (HepG2), breast (MCF7) and normal human bronchial epithelial 
(NHBE) cell line. The NHBE cell line acts as positive control throughout this study. 
MTT assay, Live/Dead® Viability/Cytotoxicity assay, cell cycle analysis, annexin V 
analysis, PARP cleavage analysis, DNA fragmentation assay, Sandwich ELISA assay 
and Western analysis were performed on these CEB4 treated tumour cell lines.  
 
In summary, the MTT assay analysis confirmed that CEB4 has cytotoxic effect 
on HSC4COX2-, HSC2, CaSki, HepG2 and MCF7, and has minimal effect on normal cell 
line, NHBE. These results show that CEB4 treatment indicates suppression of viability 
of cancer cells in a dose and time dependent manner. The LIVE/DEAD®  
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Viability/Cytotoxicity Assay Kit provides a two-color fluorescence cell viability assay 
that is based on the simultaneous determination of live and dead cells with two probes 
that measure recognized parameters of cell viability: intracellular esterase activity and 
plasma membrane integrity. The IC50 values were used to treat the five tumour cell lines 
and cell death was seen in all cell lines. The control experiment with the normal cells, 
NHBE, showed no killing after treatment with CEB4. Therefore the result of this assay 
gives a visual confirmation of the MTT assay. 
 
 Cell cycle analysis suggested that cell cycle arrest in CEB4 treated cancer cells 
at G0/G1 for HSC4COX2-, CaSki and HepG2. In the analysis on MCF7 and HSC2 cells, 
CEB4 does not have any significant arrest effect at either the G0/G1 or G2/M phases. 
Detection of hypodiploid (apoptotic) sub-G1 peak population of cells in the cancer cell 
lines; HSC4COX2-, CaSki, HepG2 and MCF-7 cells except HSC2 confirms CEB4 role as 
an inducer of apoptosis.  
 
 Annexin V analysis, PARP cleavage analysis and DNA fragmentation assay 
were performed to determine whether the cytotoxic effect in the MTT assay is 
apoptotic. In annexin V analysis CEB4 treated cancer cells at their IC 50 of CEB4 for 12 
hours, induced apoptotic cell death in all cancer cell lines. There were no changes in the 
normal cell line NHBE. The flow cytometry analysis confirms that cytotoxicity in the 
MTT assays caused apoptotic mediated cell death. PARP cleavage analysis further 
confirmed apoptosis where Western blots results show PARP cleavage in all five CEB4 
treated cancer cell lines.  
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 Due to limitation of CEB4 compound and the cancer cell lines with the 
prominent results for flow cytometry and PARP analysis, HSC4COX2- and HSC2, were 
further investigated using the DNA fragmentation assay. The compound CEB4 was 
confirmed to induce apoptotic mediated cell death as observed through the activation 
endonucleases-mediated nucleosome excision leading to the observation of DNA 
laddering of about 180-200 base pairs. HSC4COX2- and HSC2 cells demonstrated 
fragmentation of genomic DNA after 12 and 24 hours of CEB4 treatment respectively, 
which represent one of the major hallmarks of apoptosis. 
 
Results from the ELISA assay shows that treatment of tumour cells with CEB4 
stimulates phosphorylation of p53 at Ser15, detected by PathScan® Phospho-p53 
(Ser15) Sandwich ELISA kit without affecting the level of total p53 protein, detected by 
PathScan® Total p53 Sandwich ELISA kit. The highest increment of phosphorylated 
p53 is in HSC4COX2- cells, followed by HSC2, CaSki, HepG2 and MCF7 which are in 
accordance with the apoptotic analysis carried out in this study. 
 
The result of the p53 ELISA analysis suggest that CEB4 anti-cancer regulation 
may be mediated by this important tumor suppressor gene. The aim of the Western 
analysis on CEB4 treated HSC4COX2- cells were to analyze expression of p53 related 
apoptotic proteins and to understand their regulation modulated by this compound. The 
expression of p53 and other p53 signaling related apoptotic proteins such as total p53, 
phosphorylated p53, Mdm2, Bcl-2, Bax, activator caspase 9 and executioner caspase 3 
were labeled with respective monoclonal antibodies were analyzed. 
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 Western blot results demonstrated that CEB4 causes growth arrest and apoptosis 
in HSC4COX2-, and the apoptotic effect of CEB4 appeared to be mediated by the 
regulation of p53, phosphorylated p53, Mdm2, Bcl-2, Bax, activator caspase 9 and 
executioner caspase 3. Induction of apoptosis by CEB4 may involve p53 signaling 
pathway because there is an increased expression of p53 and decreased in expression of 
the p53 inhibitor, Mdm2. CEB4 up-regulates pro-apoptotic genes, Bax, and at the same 
time down-regulate the anti-apoptotic genes, Bcl-2. It also activates activator caspase 9 
and executioner caspase 3, which are downstream molecules to induce apoptosis.  
 
 These results demonstrate the cytotoxic and apoptotic ability of erythrocarpine E 
or CEB4. It warrants further investigation because of its potential use as a cancer 
chemopreventive agent. 
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